



Evidence-based clinical practice guidelines for
IgA nephropathy 2014

メタデータ	言語: eng 出版者: 公開日: 2023-02-24 キーワード (Ja): キーワード (En): 作成者: 小松, 弘幸, Yuzawa, Yukio, Yamamoto, Ryohei, Takahashi, Kazuo, Katafuchi, Ritsuko, Tomita, Makoto, Fujigaki, Yoshihide, Kitamura, Hiroshi, Goto, Masashi, Yasuda, Takashi, Sato, Mitsuhiro, Urushihara, Maki, Kondo, Shuji, Kagami, Shoji, Yasuda, Yoshinari, Takahara, Miki, Harabuchi, Yasuaki, Kimura, Kenjiro, Matsuo, Seiichi メールアドレス: 所属:
URL	http://hdl.handle.net/10458/00010531

Evidence-based clinical practice guidelines for IgA nephropathy 2014

Yukio Yuzawa¹ · Ryohei Yamamoto² · Kazuo Takahashi¹ · Ritsuko Katafuchi³ · Makoto Tomita¹ · Yoshihide Fujigaki⁴ · Hiroshi Kitamura⁵ · Masashi Goto⁶ · Takashi Yasuda⁷ · Mitsuhiro Sato⁸ · Maki Urushihara⁹ · Shuji Kondo⁹ · Shoji Kagami⁹ · Yoshinari Yasuda¹⁰ · Hiroyuki Komatsu¹¹ · Miki Takahara¹² · Yasuaki Harabuchi¹² · Kenjiro Kimura¹³ · Seiichi Matsuo¹⁰

Published online: 20 April 2016

© The Author(s) 2016. This article is published with open access at Springerlink.com

Preface

1. Background of this guideline

Immunoglobulin A (IgA) nephropathy (IgAN) is the most common primary glomerulonephritis, and patients typically require dialysis when the disease progresses to end-stage renal failure. As the incidence of IgAN is high in Asian populations, including Japanese, establishing a treatment strategy in Japan is strongly warranted. In 1995, the joint committee of the Special Study Group of the Progressive Renal Dysfunction Research Group of the Ministry of Health Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for IgAN for the first time. Its second version was published with a partial amendment in 2002.

In 2011, the Research for Progressive Kidney Diseases of Ministry of Health and Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) established the collaborative clinical guidelines committee, which published JSN and MHLW Evidence-Based Clinical Practice Guidelines for IgA nephropathy 2014 in *Nihon Jinzo Gakkai Shi*, 2015;57(1):5–137. This is the English version of that report, which was uploaded on JSN website on July 27, 2015.

✉ Yukio Yuzawa
yukio-y@fujita-hu.ac.jp

¹ Fujita Health University School of Medicine, Toyoake, Japan

² Osaka University Graduate School of Medicine, Suita, Japan

³ National Fukuoka-Higashi Medical Center, Koga, Japan

⁴ Teikyo University School of Medicine, Tokyo, Japan

⁵ Chiba East Hospital, Chiba, Japan

⁶ Kyoto Medical Center, Kyoto, Japan

⁷ Kichijoji Asahi Hospital, Tokyo, Japan

The third version, published in 2011, analyzed data from a multicenter study conducted mainly by the Research Group for IgAN in the Progressive Renal Dysfunction Research Group of MHLW to propose a novel prognostic classification (risk stratification for dialysis), adding clinical severity to histological severity. These clinical practice guides present clear prognostic criteria and treatment guidelines according to the criteria. Therefore, these guides have been widely used in clinical practice or pathological diagnosis, and they have contributed to the diagnosis and treatment of IgAN in Japan.

Meanwhile, Kidney Disease: Improving Global Outcomes (KDIGO) internationally published the Clinical Practice Guidelines for Glomerulonephritis in 2011. Recommendation grades based on the systematic review of clinical studies and the quality of evidence as a basis for determination of the strength of the recommendations are shown in the KDIGO Clinical Guidelines for Glomerulonephritis. IgAN is described in Chap. 10. However, careful evaluation was required to verify whether the KDIGO Clinical Guidelines for Glomerulonephritis was applicable to the actual clinical situation of IgAN in Japan,

⁸ JCHO Sendai Hospital, Sendai, Japan

⁹ Tokushima University Graduate School, Tokushima, Japan

¹⁰ Nagoya University Graduate School of Medicine, Nagoya, Japan

¹¹ University of Miyazaki Hospital, Miyazaki, Japan

¹² Asahikawa Medical University, Asahikawa, Japan

¹³ St. Marianna University School of Medicine, Kawasaki, Japan

because in Japan, IgAN has been detected in routine checkups in the early stage, prognosis of IgAN has been classified in many cases according to the third version of the Clinical Guides for IgAN, and tonsillectomy has been performed in many cases. Therefore, establishing practice guidelines for IgAN that are adjusted to the situation in Japan is warranted. Responding to this need, the Progressive Renal Dysfunction Research Group of MHLW and JSN decided to develop the evidence-based Clinical Guidelines for IgA Nephropathy 2014. Thus, they established the Clinical Guidelines for IgA Nephropathy 2014 Advisory Committee. Against this background, the Clinical Guidelines for IgA Nephropathy 2014 was published. It is the first-ever-published comprehensive guideline only focusing on IgAN.

2. The intended purpose, anticipated users, and predicted social significance of the guidelines

The purpose of the Clinical Guidelines for IgA Nephropathy 2014 was to define evidence-based clinical guidelines that reflect the clinical situation of IgAN in Japan. This guideline is developed to provide answers to clinical questions (CQ) that nephrologists may encounter in the clinical practice for the treatment of IgAN. Each answer is shown as a statement, and recommendation grades based on the evidence-based levels are noted for each statement in the Treatment section. It was not aimed at creating an exhaustive textbook but at supporting clinical decisions by answering questions raised by nephrologists in clinical practice and establishing a standard treatment. With the aim of comprehensively supporting nephrologists in the treatment of IgAN in clinical settings, the Clinical Guidelines for IgA Nephropathy 2014 Advisory Committee independently evaluated the results of principal randomized parallel-group clinical trials published to date and presented the scheme of indications for preventive intervention of renal dysfunction progression in this guideline. Now, patients with IgAN at any stage can be treated by using this guideline in combination with the Evidence-based Practice Guideline for the Treatment of Chronic Kidney Disease (CKD). The Clinical Guidelines for IgA Nephropathy 2014 also describe the characteristics and treatment of pediatric IgAN.

Evidence from the literature can provide information but is not a substitute for the specialized skills and experiences of individual physicians. Whether a particular statement applies and how it applies to a particular patient depends on the specialist abilities of each physician. The times demand that medical care shift from a one-size-fits-all approach to a tailor-made approach. Clinical guidelines are not supposed to impose a uniform style of care on physicians. Each physician needs to determine what kind of care each patient

needs based on an understanding of the content of clinical guidelines. As such, these guidelines are not intended to limit physicians to certain forms of medical behavior but were created to assist them in exercising their discretion to decide the type of care to be provided. In addition, it should be stated clearly that these guidelines are not criteria for deciding physician–patient conflicts or medical malpractice lawsuits.

3. Patients within the scope of the guidelines

These guidelines apply to IgAN patients of all ages. In the KDIGO Clinical Practice Guidelines, atypical IgAN is a minimal-change condition, in which IgA deposits are observed in the mesangium, is an acute renal insufficiency with gross hematuria, and presents as crescentic IgAN. Accordingly, the present guidelines recommend the aforementioned conditions should be treated as special types of IgAN. A summary of pediatric diagnostic and treatment modalities was also included.

Cases requiring CKD management were addressed based on the “2013 CKD Clinical Guideline Based on Evidence.” Finally, pregnancy-related items were, as a rule, not included.

4. Preparation procedure

Creating evidence-based guidelines first requires the enormous task of gathering and evaluating evidence. We would like to sincerely thank the members of the IgAN Clinical Guidelines Working Group for their dedication and effort. (show list of contributors)

The first meeting of the clinical guidelines working group was held on September 23, 2011. The group was led by Dr. Kenjiro Kimura of the St. Marianna University School of Medicine, who explained the significance of creating the guidelines and the procedures for the task. The IgAN clinical guidelines committee first met on October 14, during which members of the IgAN Clinical Guidelines Working Group set about creating the guidelines based on a shared understanding. In effect, this was the initial stage of the drafting of the guidelines. The MINDS handbook for creating clinical guidelines was followed, and the Delphi method was used in composing CQ, which is the core of the guidelines. Recommendation grades were determined by an informal consensus. As a rule, PubMed records up to July 2012 were used to search the literature. If necessary, important studies from after this date were included, with reasons given.

The IgAN clinical guidelines committee met 12 times, although the group also often communicated through e-mail. Through this process, the initial CQ and text items

were revised as needed, and a few deletions and additions were made. From September 13 to October 13, 2013, each part was reviewed by two designated referees and two designated academic societies. Simultaneously, public comments were solicited from members of the Japanese Society of Nephrology (JSN). The manuscript was then revised based on the referees' opinions and public comments. The IgAN clinical guidelines committee met on January 26, 2014, to examine the revised manuscript. Afterward, additional revisions were made as needed until a final draft was obtained. The guidelines, as well as responses to the referees' opinions and public comments, were posted on the JSN Web site.

5. Contents of the guideline

The guidelines are composed of three chapters as follows: I. Concepts, II. Diagnosis, and III. Epidemiology and Prognosis. These guidelines were created in tandem with the "2013 CKD Clinical Guideline Based on Evidence," and so were written by the same authors.

Items in the structured abstracts attached to the guidelines were standardized to contain the reference number, reference title, Japanese title, evidence level, author names, journal name, publication year/page, objectives, study design, subject patients, intervention factors, primary outcomes, results, and discussion.

6. Evidence levels and recommendation grades

Evidence levels were evaluated in a manner similar to that described in the "2013 CKD Clinical Guideline Based on Evidence."

[Evidence levels]

Level 1: Systematic review/meta-analysis.

Level 2: At least 1 randomized controlled trial (RCT).

Level 3: A non-RCT.

Level 4: An analytical epidemiologic study (cohort study or case-control study) or a single-arm intervention study (no controls).

Level 5: A descriptive study (case report or case series).

Level 6: Opinion of an expert committee or an individual expert, which is not based on patient data.

Evidence levels for meta-analyses and systematic reviews were determined from the designs of the studies on which they were based. If the underlying studies had mixed designs, consensus was reached to adhere to the lowest level (e.g., a meta-analysis of cohort studies would be level 4, as would a meta-analysis that included both RCT and cohort studies).

Consensus was also reached to assign evidence level 4 to all RCT subanalyses and post hoc analyses. Therefore,

an RCT with a clear primary outcome would be considered level 2, while a subanalysis or post hoc analysis of this RCT would be considered level 4.

The following recommendation grades were assigned to statements about treatments, which were based on the level of evidence for each statement.

[Recommendation Grades]

Grade A: Strongly recommended because the scientific basis is strong.

Grade B: Recommended because there is some scientific basis.

Grade C1: Recommended despite having only a weak scientific basis.

Grade C2: Not recommended because there is only a weak scientific basis.

Grade D: Not recommended because scientific evidence shows treatment to be ineffective or harmful.

As a rule, standard treatments in Japan were recommended, but eligibility for health insurance coverage was not necessarily required. Drugs ineligible for insurance coverage were denoted as such. Recommendation grades were assigned to statements about treatment-related CQ. In addition, questions such as "To which subgroup would this be recommended?" and "To which subgroup would this not be recommended?" were addressed whenever possible. Recommendation grades were decided through consultations among the working group members by considering the tradeoffs between and balance of benefits, damage, side effects, and risk. If differing views existed among the referees or in the public comments, the group reexamined the area through an exchange of opinions. The reasons for choosing a recommendation grade and the decision-making process involved were described in the commentary, as a rule.

7. Issues on the preparation of this guideline

Although evidence concerning IgAN is gradually increasing in Japan, it is still insufficient, which means that these guidelines were heavily influenced by evidence from Europe and the United States. Whether the results of clinical research from the West can be applied as is to Japan is a question that deserves careful consideration. Only a few large clinical studies have been performed on IgAN even in the West, so the quality of evidence is limited. In creating these guidelines, we strove to ensure that they would not deviate greatly from the clinical practice in Japan.

8. Financial sources and conflict of interest

The funds used in creating the guidelines were provided by a research group on progressive kidney disorders funded by the Ministry of Health, Labour, and Welfare's research

project for overcoming intractable diseases. These funds were used to pay for transportation to and from meetings, to rent space for meetings, and for box lunches and snacks. The committee members received no compensation. Everyone involved in creating the guidelines (including referees) submitted conflict-of-interest statements based on academic society rules, which are managed by JSN. Opinions were sought from multiple referees and related academic societies to prevent the guidelines from being influenced by any conflicts of interest. Drafts were shown to the society members, and revisions were made based on their opinions (public comments).

9. Publication and future revisions

The guidelines are to be published in Japanese-language journal of JNS and concurrently released in book form by Tokyo Igakusha. They will also be posted on the JSN Web site and on the MINDS Web site of the Japan Council for Quality Health Care.

I. Introduction

1. Definition and background

IgA nephropathy (IgAN, also known as Berger's disease) is a disease characterized by urinary findings suggesting glomerulonephritis; predominantly, IgA is deposited in the glomeruli, with no evidence of other underlying disease. Glomerular hematuria and proteinuria are urinary findings that suggest glomerulonephritis. Renal biopsy findings, which are required for confirming the diagnosis of glomerulonephritis, include IgA deposits mainly in the glomerular mesangium and occasionally in the capillary loops. In many cases, C3 is also co-deposited. The rate of progression to end-stage renal disease (ESRD) is approximately 40 % at 20 years after diagnosis. Treatment may include therapy with renin-angiotensin system (RAS) blockers, antiplatelet agents, oral corticosteroids, fish oil, or non-steroidal immunosuppressive agents; steroid pulse therapy; or tonsillectomy. The therapeutic effects of each have been examined, but an effective treatment regimen is yet to be established.

2. Pathogenesis and pathophysiology

1. Overview

In patients with IgAN, for some unknown reason, the level of nephritogenic IgA1 increases in the circulation and is deposited in the mesangium, leading to glomerular damage. The exact mechanism of IgAN is unknown.

Exacerbation in patients with upper respiratory infections has been well known, thereby suggesting changes in mucosal immunity are involved in the pathogenesis. Many other mechanisms are also involved in the pathogenesis of IgAN: production and increase of pathogenic IgA1, IgA1 deposition into the glomeruli, proliferation of mesangial cells and matrix expansion from the deposits, and persistent and progressive glomerulonephritis. A genetic predisposition may also play a role in the pathogenesis of IgAN.

2. Genetics

Most cases of IgAN are sporadic, but approximately 10 % are familial cases. Regional and ethnic differences are also seen in sporadic IgAN, and polygenic inheritance is found to be involved. The responsible genes differ between sporadic and familial IgAN, and genetic involvement in the disease may be monogenic or polygenic, depending on the individual or family. Pedigrees with autosomal dominant transmission have also been reported. Recent genome-wide association studies (GWAS), in which whole-gene association analysis is applied, have highlighted important findings.

3. Abnormal IgA molecules

Approximately half of all patients with IgAN have elevated levels of serum IgA, associated with increased IgA1 production from the bone marrow and/or mucosa. The IgA1 deposited in the glomeruli is from the circulating IgA1, and the serum IgA1 in patients with IgAN has been analyzed in detail. Serum IgA1 has clustered O-linked glycans on its hinge-region. Aberrantly glycosylated IgA1, i.e., galactose (Gal)-deficiency in some O-glycans, is increased in serum IgA1 and IgA1 extracted from the glomeruli.

4. Mucosal immunity

Some patients with IgAN have worsening clinical symptoms with macroscopic hematuria after upper respiratory or gastrointestinal infections, thereby suggesting a relationship between IgAN and mucosal immunity. Increased polymeric IgA1 in the circulation of patients with IgAN after an upper respiratory infection, and improvement in nephropathy after tonsillectomy, have been reported. Abnormal mucosal reactions may increase circulating polymeric IgA1, thus leading to glomerular deposition.

5. IgA1 glomerular deposition

IgA1 is selectively deposited in patients with IgAN; IgA1 has an affinity to the mesangium, especially the dimeric and polymeric IgA1 with J chains, and acidic IgAN

containing λ light chains. In addition, the deposited IgA1 has abnormal hinge-region O-linked glycans. High-molecular-weight IgA1, including serum polymeric IgA1, is deposited in the glomeruli.

6. Glomerular damage

Mesangial cell activation and complement activation through IgA deposition lead to glomerulonephritis, followed by podocyte and renal tubular injury. Humoral factors released from the mesangial cells play an important role in podocyte injury and tubulointerstitial damage (glomerulus-podocyte-renal tubule cross-talk).

II. Diagnosis

1. Diagnosis

Although various attempts have been made to diagnose IgAN according to clinical findings, IgAN is diagnosed on the basis of renal biopsy findings. On immunohistochemical study, IgAN is defined as dominant staining with IgA in a glomerulus. Histological findings such as in Henoch-Schönlein purpura nephritis (IgA vasculitis), lupus nephritis, and nephritis associated with liver cirrhosis and rheumatoid arthritis are similar to those in IgAN; therefore, a differential diagnosis should be based on clinical characteristic and laboratory data.

2. Clinical manifestations and laboratory findings

1. Clinical symptoms and physical examination findings

Most cases of IgAN are characterized by asymptomatic urinary abnormalities. Acute nephritic syndrome or evaluation of edema due to nephrotic syndrome may also lead to the diagnosis of IgAN. Macroscopic hematuria occurs in conjunction with an acute upper respiratory infection in some cases. However, macroscopically, no specific findings related to IgAN are observed in the palatine tonsils. In IgAN patients with progressively deteriorating renal function, moderate to severe proteinuria, followed by hypertension and a decline in renal function usually occurs in order.

2. Urinalysis findings

Most patients with IgAN have asymptomatic hematuria or proteinuria; this urinary abnormality leads renal biopsy. Therefore, urinalysis is essential for the diagnosis of IgAN. Currently, routine urinalysis will not show findings specific for IgAN. The Clinical Guidelines for IgA Nephropathy

(ver. 3) state that persistent microscopic hematuria is an essential finding, and intermittent or persistent proteinuria is a frequently associated finding. Moreover, macroscopic hematuria may be an incidental finding. To confirm reproducibility and persistence of the urinary abnormality, the results of at least 3 urinalyses should be considered before confirming the diagnosis. Furthermore, urinalysis on at least 2 of these occasions should, besides qualitative dipstick testing, also include analysis of urinary sediment. No urinary biomarker has yet been established to diagnose IgAN.

3. Blood biochemistry findings

No specific blood test results have been established for a diagnosis of IgAN. A frequent finding in about half of patients is elevated serum IgA levels (≥ 315 mg/dL). In addition, a high serum IgA/C3 ratio is also reported as a useful finding for differential diagnosis. At the research level, serum levels of aberrantly glycosylated IgA1, related immune complexes, and corresponding antibodies are reported to be useful as blood biomarkers of IgAN.

4. Indications for renal biopsy

Clinically, persistent microscopic hematuria and proteinuria, elevated serum IgA level, a high serum IgA/C3 ratio, and macroscopic hematuria with upper respiratory infection are strong indicators of IgAN. However, a renal biopsy is essential for a definitive diagnosis of IgAN. In addition, a renal biopsy for histopathological examination is also important for patient management, because clinical and laboratory findings alone are insufficient for assessing prognosis and selecting the appropriate treatment modality. In patients who only have asymptomatic microscopic hematuria or trace proteinuria, patient management strategy will rarely be altered by histological findings, so a renal biopsy may be optional. However, renal biopsy should be considered to differentiate between thin basement membrane disease and Alport syndrome.

5. Features of childhood IgA nephropathy

Childhood IgA nephropathy in Japan is usually found on urinary screening in schools, often leading to prompt diagnosis and initiation of treatment.

3. Pathological findings

IgAN is defined as glomerulonephritis with predominant IgA deposits in the mesangium, and kidney biopsy is essential for its diagnosis. Histological changes in IgAN mainly involve the mesangium, but various glomerular

lesions other than those in the mesangium also occur; for instance, tubular, interstitial, and vascular lesions may also develop. Precise definitions have recently been proposed for the various lesions that develop in IgAN, and examination of the lesions based on these definitions is now recommended. Pathologic diagnosis is important not only for diagnosing IgAN but also for assessing the prognosis of kidney function.

4. Classification

Classification should be useful for predicting prognosis and selecting an appropriate treatment regimen. Although various classifications have been reported so far, not one has achieved worldwide consensus. Recently, the Clinical Guidelines for IgA Nephropathy (ver. 3) published in Japan (31) and histologic classification based on a multicenter case–control study on IgAN in Japan have been put forth (Table 1A–C). At the international level, the Oxford Classification has been published (Table 2). Thus, the management of IgAN will be based on these guidelines and classification. Both classifications should be modified on the basis of the findings of further validation studies in the future.

5. Atypical forms of IgA nephropathy

1. Minimal change nephrotic disease (MCD) with mesangial IgA deposits

Rarely, in some patients with nephrotic syndrome, the kidney biopsy shows minimal glomerular changes on light microscopy, and predominant glomerular deposits of IgA on immunohistochemical study. Because prompt, complete remission after corticosteroid therapy and the following clinical course, with frequent nephrotic syndrome relapses, are very suggestive of minimal change nephrotic disease (MCD), a coincidence of MCD and IgAN has been proposed as the most likely explanation for such cases. Nephrotic syndrome occurs in 5–25 % of all patients with IgAN, and the coincidence of MCD among these patients is 25–47 % (1.8–6 % of all patients with IgAN).

2. Acute kidney injury (AKI) associated with macroscopic hematuria

Episodic macroscopic hematuria coinciding with mucosal infection is a hallmark of IgAN. The macroscopic hematuria usually resolves spontaneously in a few days, and kidney function usually recovers completely after the disappearance of macroscopic hematuria. However, in rare cases, the macroscopic hematuria is prolonged and acute kidney injury (AKI) develops. AKI occurs in less than 5 %

of the patients with IgAN. Histologically, crescent formation and obstruction of tubules by red blood cell casts and tubular epithelial cell injury are frequently observed. AKI cannot be explained by the percentage of crescent formation in the glomerulus alone, and many studies have reported that AKI is mainly caused by red blood cell casts and the resulting renal tubular epithelial injury. In a majority of patients, kidney function returns to baseline after the disappearance of macroscopic hematuria, but incomplete recovery of kidney function has been reported in up to 25 % of the affected patients in long-term follow-up studies. Macroscopic hematuria lasting longer than 10 days is the most significant risk factor of persistent kidney impairment.

3. Crescentic IgA nephropathy

Crescentic IgAN is defined by different studies according to the percentage of the glomeruli with crescent formation ranging between 10 and 80 % of the glomeruli with crescent formation. Crescentic IgAN was found to account for 5 % of all IgAN cases in a study that used a definition of crescentic IgAN as more than 30 % of the glomeruli with crescent formation and for 1.14 % of all IgAN cases in a study that used a definition of crescentic IgAN as more than 50 % of the glomeruli with crescent formation. The histopathological analysis yields not only active lesions such as widespread cellular crescents, endocapillary hypercellularity, and tuft necrosis, but also a varying degree of chronic lesions such as glomerular sclerosis and interstitial fibrosis. Clinical manifestations include rapidly progressive glomerulonephritis, hypertension, severe proteinuria, and frequently macroscopic hematuria. Steroid and cyclophosphamide therapy may be effective in crescentic IgAN, but their effectiveness remains controversial.

III. Epidemiology, prognosis, and follow-up

1. Incidence and prevalence

In Japan, about one-third of all patients who undergo renal biopsy are diagnosed with IgAN. The incidence of IgAN is estimated to be 3.9 to 4.5 per 100,000 persons per year. An estimated 33,000 persons have IgAN (95 % CI 28,000–37,000).

2. Natural course

The 10-year renal survival rate in adult-onset IgAN is approximately 80–85 %. The 10-year renal survival rate in childhood-onset IgAN is over 90 %.

Table 1 Histologic classification presented by a multicenter case–control study on patients with IgAN in Japan

Histological grade	% glomeruli with pathological variables** predicting progression to ESRD	Acute lesion only	Acute and chronic lesion	Chronic lesion only
A. Histological grade				
H-Grade I	0–24.9 %	A	A/C	C
H-Grade II	25–49.9 %	A	A/C	C
H-Grade III	50–74.9 %	A	A/C	C
H-Grade IV	>75 %	A	A/C	C
Clinical grade	Proteinuria (g/day)	EGFR (ml/min/1.73 m ²)		
B. Clinical grade				
C-Grade I	<0.5	–		
C-Grade II	0.5 ≤	60 ≤		
C-Grade III		<60		
Clinical grade	Histological grade			
	H-Grade I	H-Grade II	H-Grade III + IV	
C. Grading system for predicting progression to ESRD				
C-Grade I	Low	Moderate	High	
C-Grade II	Moderate	Moderate	High	
C-Grade III	High	High	Super high	

**Acute lesion (A): cellular crescent, tuft necrosis, fibrocellular crescent

Chronic lesion (C): global sclerosis, segmental sclerosis, fibrous crescent

Low risk group: *1 of 72 (1.4 %) of IgAN patients developed to ESRD in 18.6 years after RBx

Moderate risk group: *13 of 115 (11.3 %) of IgAN patients developed to ESRD in 11.5 (3.7–19.3) years after RBx

High risk group: *12 of 49 (24.5 %) of IgAN patients developed to ESRD in 8.9 (2.8–19.6) years after RBx

Super high risk group: *22 of 34 (64.7 %) of IgAN patients developed to ESRD in 5.1 (0.7–13.1) years after RBx

* The data from retrospective multicenter case–control study on IgAN (n = 287)

Table 2 Definitions of pathological variables used in the Oxford classification

Variable	Definition	Score
Mesangial hypercellularity	<4 Mesangial cells/mesangial area = 0	M0 ≤ 0.5
	4–5 Mesangial cells/mesangial area = 1	M1 > 0.5 ^a
	6–7 Mesangial cells/mesangial area = 2	
	≥8 Mesangial cells/mesangial area = 3	
The mesangial hypercellularity score is the mean score for all glomeruli		
Segmental glomerulosclerosis	Any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion	S0—absent
		S1—present
Endocapillary hypercellularity	Hypercellularity due to increased number of cells within glomerular capillary lumina causing narrowing of the lumina	E0—absent
		E1—present
Tubular atrophy/interstitial fibrosis	Percentage of cortical area involved by the tubular atrophy or interstitial fibrosis, whichever is greater	T0—0–25 %
		T1—26–50 %
		T2—>50 %

^a Mesangial score should be assessed in periodic acid-Schiff-stained sections. If more than half the glomeruli have more than three cells in a mesangial area, this is categorized as M1. Therefore, a formal mesangial cell count is not always necessary to derive the mesangial score

3. Changes in prognosis with changes in treatment guidelines

Various studies show that the prognosis of IgAN is better in patients diagnosed in the 1990s and later than in patients diagnosed before then, suggesting that changes in treatment guidelines for IgAN have been successful.

4. Clinical predictors of progression at the time of initial examination or renal biopsy

Clinical predictors of progression in patients with IgAN at the time of the initial examination or renal biopsy include amount of proteinuria, blood pressure levels, degree of renal dysfunction, and histological severity. Therefore, models to predict the renal prognosis from the time of the initial examination or renal biopsy have been developed with combinations of these factors and are used in prognostic predictions for IgAN. 35–39) However, along with the prolonged disease duration and progression of disease, the amount of proteinuria, blood pressure level, renal function, and histological lesions progressively deteriorate. Therefore, these factors may simply reflect the stage (grade) of disease. Factors indicating the progression rate of disease at each stage (grade) of IgAN have not been identified.

5. Clinical predictors of progression during follow-up

Because multiple renal biopsies are not feasible, the clinical predictors of progression of IgAN during follow-up are proteinuria, blood pressure, and hematuria. Both the mean proteinuria level and the mean blood pressure levels during follow-up have known to be stronger risk factors for ESRD than factors like amount of proteinuria, blood pressure level, degree of renal dysfunction, and histological severity of IgAN at the time of initial examination or renal biopsy. In particular, maintaining proteinuria at <1.0 g/day and blood pressure at $<130/80$ mmHg during follow-up are associated with improved renal prognosis.

6. Remission of urinary findings and its significance

In patients with IgAN, normalization of urinary findings during the natural course or after treatment, in other words, a remission of urinary findings defined as an improvement or disappearance of hematuria and proteinuria is reported to be associated with improved renal prognosis. However, remission of urinary findings has been variously defined to date. Therefore, the significance of remission of urinary findings during the natural course or after treatment in the

renal prognosis in patients with IgAN is unclear. Studies have been initiated to standardize the definition of remission, evaluate the therapeutic effectiveness of treatment regimens based on a standard definition of remission, and clarify the significance of the remission of urinary findings. Furthermore, patients who have achieved remission of urinary findings may later again experience worsening of urinary findings, in other words, a recurrence. Recurrence after remission of urinary findings has also not been defined, and its significance is also unclear.

7. Follow-up

At present, there is no robust evidence for the follow-up protocols of IgAN to improve renal prognosis. Currently, both the degree of renal dysfunction and amount of proteinuria are used as markers in follow-up protocols. As renal dysfunction worsens and proteinuria level increases, careful monitoring of the clinical course and treatment effectiveness at shorter follow-up intervals is recommended. In addition, follow-up intervals should be adjusted according to renal biopsy findings, urinary findings, achieved blood pressure levels, the rate of progression of renal dysfunction, and the type of treatment regimen. Moreover, urinary findings may improve over a period of years after various treatments, while recurrence after improved urinary findings may occur after long period of time. Therefore, long-term follow-up is strongly recommended in patients with IgAN, even in patients with only mild urinary abnormalities.

IV. Treatment

1. A summary of management of IgAN in adults, with a focus on prevention of renal dysfunction

In Japan, the major potential treatment modalities for adult IgAN are the use of RAS blockers, corticosteroids, non-steroidal immunosuppressive agents, antiplatelet agents, and n-3 fatty acids (fish oil) and tonsillectomy (with corticosteroid pulse therapy). We evaluated the reduction of proteinuria and preservation of kidney function caused by therapeutic interventions based on the results of several randomized controlled trials (RCTs), as shown in Figs. 1 and 2. Consequently, the following guidelines have been developed for the treatment of patients with IgAN: To suppress IgAN progression, treatments should be based on renal function, urinary protein, age, and renal histopathological findings. Interventions to optimize blood pressure, salt intake, lipid and glucose metabolism, body weight, and smoking habits should be considered, if necessary (Fig. 3).




Fig. 1 The summary of randomized controlled trials of corticosteroids and immunosuppressive agents in adult patients with IgAN




Fig. 1 continued




Fig. 2 The summary of randomized controlled trials of RAS blockers, antiplatelet agents, and fish oils in adult patients with IgAN




Fig. 2 continued

**2. Clinical questions (CQs)
about immunosuppressive therapy (adults)**

<p>CQ 1. Are corticosteroids recommended in IgA nephropathy?</p>
<p>Recommendation grade: B</p> <p>To control the progression of renal dysfunction in patients with IgAN with urinary protein level C1 g/day and CKD stage G1-2, a short course of high-dose oral steroid therapy (prednisolone at dose of 0.8–1.0 mg/kg for about 2 months, followed by gradual tapering over about 6 months) is recommended.</p>
<p>Recommendation grade: B</p> <p>To control the progression of renal dysfunction in patients with IgAN with urinary protein level C1 g/day and CKD stage G1-2, steroid pulse therapy (methylprednisolone 1 g for 3 days by infusion (or IV) every other month, 3 times + prednisolone 0.5 mg/kg, every other day, for 6 months) is recommended.</p>
<p>Recommendation grade: C1</p> <p>Steroid therapy may reduce proteinuria in patients with IgAN with urinary protein level of 0.5–1.0 g/day and CKD stage G1-2, and this may also be considered a treatment option.</p>

[Summary]

To evaluate the effectiveness of corticosteroid therapy for treating IgAN, patients with IgAN with urinary protein level ≥ 1 g/day and CKD stage G1-2 were enrolled in a randomized controlled trial (RCT). A short course of high-dose oral steroid therapy (prednisolone at a dose of 0.8–1.0 mg/kg for about 2 months, followed by gradual tapering over about 6 months), along with concomitant administration of RAS blockers, improved the renal function, as seen in 2 different studies, so this regimen is recommended. Steroid pulse therapy (methylprednisolone 1 g for 3 days, every other month, 3 times + prednisolone 0.5 mg/kg, every other day, for 6 months) also improved the renal function; however, this improvement was reported in 1 study only. The validity of this result needs to be reconfirmed. Therefore, high-dose oral steroid therapy may be effective in reducing urinary protein levels for patients with IgAN with urinary protein level of 0.5–1.0 g/day and CKD stage G1-2. Nevertheless, further investigation is necessary.




Fig. 3 An outline of treatment of IgAN in adults with a focus on prevention of renal dysfunction (based on randomized controlled trials for IgAN) This figure shows the indications for treatment intervention, based mainly on the results (Figs. 1, 2) of RCTs, often focusing on renal function and amount of urinary protein excreted as patient inclusion/exclusion criteria. In actual clinical practice, besides renal function and urinary protein level, other factors such as renal histopathological findings and age should also be considered to carefully decide the indications for these treatment interventions. Others *: Tonsillectomy (combined with high-dose pulse corticosteroid therapy) and therapy with non-steroidal immunosuppressive agents, antiplatelet agents, and n-3 fatty acids (fish oil). CKD management guidelines **: The Japanese Society of Nephrology Evidence based Clinical Practice Guideline for CKD 2013: Hypertension (Chap. 4), salt intake (Chaps. 3, 4), lipid disorders (Chap. 14), glucose intolerance (Chap. 9), obesity (Chap. 15), smoking (Chap. 2), anemia (Chap. 7), CKD mineral and bone disorders (CKD-MBD, Chap. 8), and metabolic acidosis (Chap. 3) should also be managed as necessary

CQ 2. Is tonsillectomy combined with steroid pulse therapy recommended?

<p>Recommendation grade: C1</p> <p>Tonsillectomy combined with steroid pulse therapy may improve urinary findings in patients with IgAN and lower the progression of renal dysfunction. This may also be considered a treatment option.</p>
--

[Summary]

In a retrospective cohort study, Hotta et al. reported that tonsillectomy combined with steroid pulse therapy normalized urinary findings, which are predictive factors for renal failure. Additionally, in a non-randomized comparative study, Komatsu et al. reported that the normalization rate of urinary findings was higher with tonsillectomy combined with steroid pulse therapy than with steroid pulse therapy alone. However, the level of evidence is regarded as insufficient because these studies were not designed as

RCTs. At a meeting of the Japanese Society of Nephrology in 2011, the Ministry of Health, Labour and Welfare (MHLW) Progressive Renal Dysfunction Research Group stated that tonsillectomy combined with steroid pulse therapy was found to be more effective than steroid pulse therapy alone in reducing urinary protein in RCTs. This regimen was suggested as a possible treatment option for IgAN. To establish more substantial evidence, the superiority of tonsillectomy combined with steroid pulse therapy should be further investigated.

CQ 3. Is tonsillectomy (alone) recommended?

Recommendation grade: C1

Tonsillectomy may improve urinary findings in patients with IgAN and slow the progression of renal dysfunction. This may also be considered as a treatment option.

[Summary]

The efficacy of tonsillectomy has been reported since the 1980s, but different studies have yielded different results owing to differences in the levels of renal dysfunction, urinary protein, and histopathological damage. In the early 2000 s, a retrospective cohort study with a follow-up period of 11 ± 4 years showed no association between tonsillectomy and the rate of progression to ESRD. On the other hand, another study with a longer follow-up of 16 ± 6 years reported a lower incidence of ESRD in the tonsillectomy group than in the non-tonsillectomy group. Because of flaws in the design of previous studies, it is difficult to definitively conclude the efficacy of tonsillectomy. Meanwhile, previous reports show that the tonsillectomy may improve urinary findings in patients with IgAN and may lower the progression of renal dysfunction for a long period of ≥ 15 years, especially at a relatively early stage, with no serological renal dysfunction or sclerotic lesions in the glomeruli. Previous studies may have shown the efficacy of tonsillectomy in cases of IgAN for a long period, but none of these studies was a RCT. Therefore, according to current clinical practices in Japan, the Guidelines Advisory Committee has decided on a recommendation grade of C1.

CQ 4. Are non-steroidal immunosuppressive agents recommended?

Recommendation grade: C1

Cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, and mizoribine may improve the renal prognosis in patients with IgAN. They may also be considered treatment options (off-label use).

[Summary]

RCTs for the effectiveness of cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, and mizoribine for treatment of IgAN have mostly been small-scale studies with a small number of patients. Therefore, it has been difficult to reach a consensus about their effectiveness. Some studies have reported effectiveness in reducing urinary protein level and improving the prognosis of renal function. Further investigations are necessary.

3. CQs about immunosuppressive therapy (children)

CQ 5. Is immunosuppressive therapy recommended in childhood IgA nephropathy?

Recommendation grade: B

Immunosuppressive therapy is effective and recommended for reducing urinary protein level, preventing progression to glomerular sclerosis, and improving the renal prognosis in children with severe IgAN.

[Summary]

Children with IgAN can be categorized into 2 broad groups according to clinical or histological severity. For children with mild urinary protein excretion (morning urinary protein/creatinine ratio <1.0), focal mesangial proliferation, and $<30\%$ crescentic glomeruli (mild cases), non-immunosuppressive therapy with RAS blockers and/or Sairei-to (herbal medicine) is recommended. However, for children with severe urinary protein excretion (morning urinary protein/creatinine ratio ≥ 1.0), moderate or greater mesangial proliferation, crescent formation, adhesions, or sclerotic lesions (any of the above) involving $\geq 80\%$ of all the glomeruli or $\geq 30\%$ of crescentic glomeruli (severe cases), combination therapy with corticosteroids and non-steroidal immunosuppressive agents, anticoagulants, and antiplatelet agents is highly effective.

CQ 6. Is combination “cocktail” therapy recommended in childhood IgA nephropathy?

Recommendation grade: B

Combination therapy with corticosteroids, non-steroidal immunosuppressive agents, anticoagulants, and antiplatelet agents is recommended in severe childhood IgAN with a poor prognosis in order to reduce proteinuria, prevent progression of glomerular sclerosis, and improve the prognosis of renal function.

[Summary]

In severe childhood IgAN with diffuse mesangial proliferation, combination “cocktail” therapy for 2 years with four drugs, consisting of corticosteroids, non-steroidal immunosuppressive agents (azathioprine), anticoagulants, and antiplatelet agents, is more effective than therapy with corticosteroids alone in reducing proteinuria and preventing the progression of glomerular sclerosis. In addition, combination therapy using azathioprine is associated with a significantly higher 10-year renal survival rate than combined treatment with an anticoagulant and antiplatelet agents. Combination therapy using mizoribine has similar therapeutic effectiveness as combination therapy with azathioprine.

4. CQs about supportive therapy (adults)

CQ 7. Are RAS blockers recommended in IgA nephropathy?

Recommendation grade: A

RAS blockers control the progression of renal dysfunction in patients with IgAN with urinary protein level ≥ 1 g/day and CKD stage G1-3b; therefore, their use is recommended.

Recommendation grade: C1

RAS blockers may reduce proteinuria in patients with IgAN with urinary protein level of 0.5–1.0 g/day. They may be considered treatment options.

[Summary]

To evaluate the effectiveness of RAS blockers for treating IgAN, patients with IgAN with urinary protein level ≥ 1 g/day and CKD stage G1-3b have been enrolled in RCTs. Many studies have reported anti-proteinuric effects of RAS blockers, and 2 studies with a mean follow-up period of ≥ 5 years reported an improvement in the prognosis of renal function. Therefore, RAS blockers are recommended for patients with IgAN with urinary protein level ≥ 1 g/day and CKD stage 1–3b. The effectiveness of RAS blockers in patients with IgAN with urinary protein level < 1 g/day has not been fully evaluated. Combination therapy with ACE inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists, and renin inhibitors is an

issue requiring further investigation. RAS blockers are contraindicated in women who are pregnant or trying to conceive. RAS blockers for IgAN patients without hypertension are off-label use in Japan.

CQ 8. Are antiplatelet agents recommended in IgA nephropathy?

Recommendation grade: C1

Dipyridamole may be effective in reducing proteinuria and controlling the progression of renal dysfunction. This may be considered a treatment option.

Recommendation grade: C1

Dilazep hydrochloride (dilazep) may be effective in reducing proteinuria, and it may be considered a treatment option.

[Summary]

Only few studies have evaluated the effectiveness of antiplatelet agents (dipyridamole, dilazep, ticlopidine, and aspirin) and anticoagulants (warfarin) in adult IgAN. Therefore, their effectiveness is currently unknown. In a multicenter double-blind RCT conducted in Japan by Tojo et al. in the 1980s, a subgroup analysis showed that dipyridamole and dilazep was effective in reducing proteinuria in patients with IgAN. The effectiveness of dipyridamole and dilazep in patients with IgAN should be further investigated in meticulously planned RCTs.

CQ 9. Are n-3 fatty acids (fish oil) recommended in IgA nephropathy?

Recommendation grade: C1

The n-3 fatty acids (fish oil) may improve renal prognosis in patients with IgAN. They may be considered a treatment option.

[Summary]

Only 6 RCTs have evaluated the effectiveness of n-3 fatty acids (fish oil) in IgAN, so it has been difficult to reach a consensus about their effectiveness. In the largest and longest study involving 106 patients with IgAN, fish oil was reported to inhibit the progression to ESRD. However, other small-scale short-term studies have not confirmed the effectiveness of fish oil. Further investigation is necessary.

5. CQs about lifestyle and dietary guidance in IgA nephropathy

CQ 10. Should limitation of salt intake be recommended?

Recommendation grade: B

Limiting excess salt intake should be recommended to patients with IgAN. In patients with IgAN with hypertension and renal dysfunction, limiting salt intake helps lower the progression to ESRD and reduces the risk of cardiovascular disease and death. Therefore, limiting salt intake to 3 to 6 g/day is recommended.

Recommendation grade: C2

A relationship between low sodium intake and cardiovascular event has been reported. Therefore, salt intake of less than 3 g/day is not recommended.

[Summary]

There is no direct evidence showing that salt intake restriction is effective in patients with IgAN. However, in an intervention study of non-diabetic patients with CKD, limited salt intake helped reduce blood pressure and decrease urinary protein excretion. Because blood pressure and urinary protein are related to prognosis in IgAN, limiting salt intake is probably beneficial in these patients. Furthermore, in a cohort study involving non-diabetic patients with CKD, higher salt intake increased the risk of renal dysfunction and accelerated progression to ESRD, suggesting that limited salt intake is also a treatment option in patients with IgAN. Nevertheless, these studies were conducted outside Japan and included patients without IgAN. Therefore, the effectiveness and indications for salt intake restriction in Japanese patients with IgAN requires further investigation.

CQ 11. Should restricted protein intake be recommended?

Recommendation grade: C1

Limitation of protein intake is not uniformly recommended for all patients with IgAN. Instead, the condition of each individual patient, their risk of progressive renal dysfunction, and adherence to treatment should be considered when deciding whether to recommend protein intake restriction.

[Summary]

No direct evidence exists to show that protein restriction is effective in patients with IgAN. However, in a meta-analysis involving patients with CKD, limited protein intake did reduce the risk of ESRD and death. On the other hand, limited protein intake has not been shown to reduce

the rate of decline in the glomerular filtration rate (GFR). Moreover, severe protein restriction may increase the risk of death, especially after dialysis is initiated. Factors such as age and overall condition differ among individual patients with IgAN, so uniform protein restrictions should not be recommended to all patients. The indications for protein restrictions should be decided on the basis of comprehensive assessments, the risk of progressive renal dysfunction, and adherence to treatment. In addition, when recommending protein restrictions, caution should be taken to avoid malnutrition.

CQ 12. Should weight loss be recommended?

Recommendation grade: A

Patients with IgAN who are obese (body mass index [BMI] ≥ 25) should be advised to lose weight.

[Summary]

Patients with IgAN who are obese have higher levels of proteinuria, exhibit greater histological injury on renal biopsy associated with obesity, and have a higher future risk of hypertension and progressive renal dysfunction than non-obese patients with IgAN. Moreover, obesity increases the risk of the development and exacerbation of lifestyle-related diseases such as hypertension, diabetes, and lipid disorders. These lifestyle-related diseases adversely affect the prognosis in patients with kidney disease. Therefore, weight loss should be recommended to obese patients with IgAN. However, there is currently no evidence suggesting that weight reduction helps control renal dysfunction or reduce the level of urinary protein. Further investigation is needed.

CQ 13. Should exercise restriction be recommended?

Recommendation grade: C2

In patients with IgAN, exercise has been reported to transiently increase proteinuria, but after completion of the exercise, the urinary protein levels return to resting levels. Excessive rest (disuse) is also harmful in many conditions, and no evidence has shown that exercise worsens the prognosis in IgAN. Therefore, exercise restriction should not be recommended to patients with IgAN.

[Summary]

Exercise is reported to transiently increase urinary protein excretion in patients with IgAN. On the other hand, exercise therapy improves maximum oxygen uptake in patients with CKD. Although there is insufficient evidence regarding the effects and indications for exercise therapy in CKD, exercise restriction should not be recommended to patients with IgAN. Meanwhile, with regard to strenuous exercise, almost no evidence exists regarding the

association of exercise in CKD, with a relatively rapid decline in GFR or in CKD with severe nephrotic-level proteinuria. Therefore, the indications for exercise therapy or exercise restrictions should be based on comprehensive assessment of each individual patient's condition. These patients will require careful follow-up.

CQ 14. Should smoking cessation be recommended?

Recommendation grade: A

Smoking is associated with decreased renal function in patients with IgAN. Smoking is also a major risk factor for lung cancer, chronic obstructive pulmonary disease (COPD), and cardiovascular disease. Therefore, smoking cessation should be recommended to patients with IgAN.

[Summary]

In a cohort study of patients with IgAN in Japan and overseas, smoking and the number of cigarettes smoked per day at the time of renal biopsy were associated with a decrease in renal function. In a cohort study of the general population in Japan and overseas, current smoking was related to decreased renal function and renal failure, positive findings for proteinuria, and albuminuria. Therefore, patients with IgAN should be advised to stop smoking to prevent decreased renal function and increased proteinuria. Previous smoking is also a risk factor for renal failure and albuminuria, but the lower risks are associated with previous smoking than current smoking; therefore, smoking cessation in current smokers may potentially prevent any further decline in renal function or increase in proteinuria.

In addition, the number of cigarettes per day and cumulative smoking (pack/years) are risk factors for decreased renal function. Therefore, even when patients are unable to quit smoking, reducing the number of cigarettes smoked per day may help reduce the risk of renal dysfunction. Although no direct evidence exists to show that smoking cessation or reduction prevents deterioration in renal function or exacerbation of proteinuria, smoking itself is an important risk factor not only for renal prognosis but also for lung cancer, COPD, and cardiovascular disease. Therefore, it is important for healthcare providers to provide guidance for smoking cessation.

6. Adverse events associated with steroid therapy and immunosuppressive agents

To date, no study has shown a high rate of serious adverse events associated with steroid therapy in adult patients with IgAN. However, because it is not certain whether these

findings were based on sufficient disclosure of information, an assessment of risk factors for adverse events and preventive measures should be conducted before starting steroid therapy. Meanwhile, the indications for immunosuppressive therapy must be carefully decided after weighing the potential benefits against the potential risks, because immunosuppressive agents induce serious adverse events in some cases. A “cocktail” therapy involving a combination of corticosteroids and immunosuppressive agents has been shown to be effective in children with IgAN. However, the safety of this combination therapy must be further confirmed, because for some patients, this therapy was discontinued owing to the adverse events. Tonsillectomy in patients with IgAN has a very low rate of serious complications. Cooperation between otolaryngologists and nephrologists is essential for prevention of complications during surgery for patients on immunosuppressive therapy after kidney transplantation and to detect any remnant tonsillar tissue in the patients.

Acknowledgments All authors are advisory committee members of Clinical Guidelines for IgA Nephropathy 2014. Committee chairman: Yukio Yuzawa. Committee members: Maki Urushihara, Shoji Kagami, Ritsuko Katafuchi, Hiroshi Kitamura, Hiroyuki Komatsu, Masashi Goto, Shuji Kondo, Mitsuhiro Sato, Kazuo Takahashi, Miki Takahara, Makoto Tomita, Yasuaki Harabuchi, Yoshihide Fujigaki, Takashi Yasuda, Yoshinari Yasuda, Ryohei Yamamoto. Chief Chairman of the Clinical Practice Guidelines for Progressive Kidney Diseases: Kenjiro Kimura. Leader of the Research for Progressive Kidney Diseases of the Ministry of Health, Labour and Welfare: Seiichi Matsuo. Cooperative Medical Society: The Japanese Society for Pediatric Nephrology, The Oto-Rhino-Laryngological Society of Japan.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Bibliography

I. Introduction

1. Definition and background

1. Berger J, et al. *J Urol Nephro*(Paris)1968;74:694–5.
2. Baehr G. *JAMA* 1926;86:1001–4.
3. Bates RC, et al. *Am J Med* 1957;23:510–28.
4. Galle P, et al. *J Urol Nephro*(Paris)1962;68:123–7.
5. Cattran DC, et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. *Kidney Int* 2009;76:534–45.
6. Chauveau D, et al. *Contrib Nephrol* 1993;104:1–5.
7. Koyama A, et al. *Am J Kidney Dis* 1997;29:526–32

2. Pathogenesis and pathophysiology

1. Overview

1. Coppo R, et al. *J Nephrol* 2010;23:626–32.
2. Suzuki Y, et al. *Clin Dev Immunol* 2011;2011:639074.
3. Donadio JV, et al. *N Engl J Med* 2002;347:738–48.
4. Boyd JK, et al. *Kidney Int* 2012;81:833–43.
5. Narita I, et al. *Clin Exp Nephrol* 2008;12:332–8.
6. Floege J. *Am J Kidney Dis* 2011;58:992–1004.
7. Suzuki H, et al. *J Am Soc Nephrol* 2011;22:1795–803.
8. Mestecky J, et al. *Annu Rev Pathol* 2013;8:217–40.
9. Novak J, et al. *Semin Immunopathol* 2012;34:365–82.
10. Gharavi AG, et al. *Nat Genet* 2011;43:321–7.
11. Kiryluk K, et al. *PLoS Genet* 2012;8:e1002765.
12. Berger J, et al. *Kidney Int* 1975;7:232–41.
13. Berger J. *Am J Kidney Dis* 1988;12:371–2.
14. Ponticelli C, et al. *Kidney Int* 2001;60:1948–54.
15. Floege J. *Semin Nephrol* 2004;24:287–91.
16. Sanfilippo F, et al. *Transplantation* 1982;33:370–6.
17. Silva FG, et al. *Transplantation* 1982;33:241–6.
18. Cuevas X, et al. *Transplant Proc* 1987;19:2208–9.
19. Iwata Y, et al. *Intern Med* 2006;45:1291–5.
20. Zickerman AM, et al. *Am J Kidney Dis* 2000;36:E19.
21. Van Der Helm–Van Mil AH, et al. *Br J Haematol* 2003;122:915–7.
22. Pouria S, et al. *Semin Nephrol* 2008;28:27–37.
23. Glasscock RJ. *Curr Opin Nephrol Hypertens* 2011;20:153–60.
24. Mestecky J. *Am J Kidney Dis* 1988;12:378–83.
25. Conley ME, et al. *J Clin Invest* 1980;66:1432–6.
26. van der Boog PJ, et al. *Kidney Int* 2005;67:813–21.
27. Suzuki K, et al. *Kidney Int* 2003;63:2286–94.
28. Moura IC, et al. *Semin Nephrol* 2008;28:88–95.
29. Hiki Y. *Clin Exp Nephrol* 2009;13:415–23.
30. Monteiro RC, et al. *Annu Rev Immunol* 2003;21:177–204.
31. Berthelot L, et al. *J Exp Med* 2012;209:793–806.
32. Lai KN. *Nat Rev Nephrol* 2012;8:275–83.
33. Feehally J, et al. *J Am Soc Nephrol* 2010;21:1791–7.
34. Yu XQ, et al. *Nat Genet* 2011;44:178–82.
35. Macpherson AJ, et al. *Trends Immunol* 2012;33:160–7.

2. Genetics

1. Johnston PA, et al. *Q J Med* 1992;84:619–27.
2. Rambašek M, et al. *Pediatr Nephrol* 1987;1:416–8.
3. Paterson AD, et al. *J Am Soc Nephrol* 2007;18:2408–15.
4. Gharavi AG, et al. *Nat Genet* 2011;43:321–7.
5. Yu XQ, et al. *Nat Genet* 2011;44:178–82.
6. Kiryluk K, et al. *PLoS Genet* 2012;8:e1002765.
7. Gharavi AG, et al. *Nat Genet* 2000;26:354–7.
8. Bisceglia L, et al. *Am J Hum Genet* 2006;79:1130–4.
9. Karnib HH, et al. *Nephrol Dial Transplant* 2007;22:772–7.
10. Frascá GM, et al. *J Nephrol* 2004;17:778–85.
11. Takei T, et al. *Am J Hum Genet* 2002;70:781–6.
12. Akiyama F, et al. *J Hum Genet* 2002;47:532–8.

13. Obara W, et al. *J Hum Genet* 2003;48:293–9.
14. Ohtsubo S, et al. *J Hum Genet* 2005;50:30–5.
15. Feehally J, et al. *J Am Soc Nephrol* 2010;21:1791–7.
16. Imielinski M, et al. *Nat Genet* 2009;41:1335–40.
17. Kiryluk K, et al. *Annu Rev Med* 2013;64:339–56.
18. Kiryluk K, et al. *Pediatr Nephrol* 2010;25:2257–68.
19. Gharavi AG, et al. *J Am Soc Nephrol* 2008;19:1008–14.
20. Tam KY, et al. *Kidney Int* 2009;75:1330–9.
21. Kiryluk K, et al. *Kidney Int* 2011;80:79–87.
22. Li GS, et al. *Kidney Int* 2007;71:448–53.
23. Pirulli D, et al. *J Nephrol* 2009;22:152–9.
24. Zhu L, et al. *Kidney Int* 2009;76:190–8.
25. Li GS, et al. *Hum Mutat* 2007;28:950–7.
26. Malycha F, et al. *Nephrol Dial Transplant* 2009;24:321–4.
27. Suzuki K, et al. *Kidney Int* 2003;63:2286–94.
28. Floege J. *Am J Kidney Dis* 2011;58:992–1004.
29. Miyazaki M. *Jpn J Med* 1990;29:469–77.

3. Abnormal IgA molecules

1. van der Boog PJ, et al. *Kidney Int* 2005;67:813–21.
2. Mestecky J, et al. *Contrib Nephrol* 1993;104:172–82.
3. Allen AC. *Nephrol Dial Transplant* 1995;10:1121–4.
4. Hiki Y, et al. *Contrib Nephrol* 1995;111:73–84.
5. Hiki Y, et al. *Kidney Int* 2001;59:1077–85.
6. Allen AC, et al. *Kidney Int* 2001;60:969–73.
7. Mattu TS, et al. *J Biol Chem* 1998;273:2260–72.
8. Mestecky J, et al. *Mucosal Immunology*, 3rd ed. 2005, pp153–81.
9. Peppard JV, et al. *Mucosal Immunology*, 3rd ed. 2005, pp195–210.
10. Tarelli E, et al. *Carbohydr Res* 2004;339:2329–35.
11. Renfrow MB, et al. *J Biol Chem* 2005;280:19136–45.
12. Iwasaki H, et al. *J Biol Chem* 2003;278:5613–21.
13. Takahashi K, et al. *Mol Cell Proteomics* 2010;9:2545–57.
14. Takahashi K, et al. *J Proteome Res* 2012;11:692–702.
15. Novak J, et al. *Semin Nephrol* 2008;28:78–87.
16. Ju T, et al. *Nature* 2005;437:1252.
17. Schachter H, et al. *J Biol Chem* 1971;246:5321–8.
18. Moldoveanu Z, et al. *Kidney Int* 2007;71:1148–54.
19. Shimozato S, et al. *Nephrol Dial Transplant* 2008;23:1931–9.
20. Wada Y, et al. *J Proteome Res* 2010;9:1367–73.
21. Smith AC, et al. *J Am Soc Nephrol* 2006;17:1192–9.
22. Suzuki H, et al. *J Clin Invest* 2008;118:629–39.
23. Malycha F, et al. *Nephrol Dial Transplant* 2009;24:321–4.
24. Serino G, et al. *J Am Soc Nephrol* 2012;23:814–24.
25. Yamada K, et al. *Nephrol Dial Transplant* 2010;25:3890–7.
26. Buck KS, et al. *Kidney Int* 2008;73:1128–36.
27. Lai KN, et al. *Kidney Int* 1988;33:584–9.
28. Chui SH, et al. *J Clin Immunol* 1991;11:219–23.
29. Leung JC, et al. *J Lab Clin Med* 1999;133:152–60.
30. Amore A, et al. *J Am Soc Nephrol* 2001;12:1862–71.
31. Leung JC, et al. *J Clin Lab Anal* 2002;16:11–9.

32. Odani H, et al. *Biochem Biophys Res Commun* 2000;271:268–74.
 33. Xu LX, et al. *Kidney Int* 2005;68:167–72.
 34. Ding JX, et al. *Clin Immunol* 2007;125:268–74.
 35. Maenuma K, et al. *J Proteome Res* 2009;8:3617–24.
 36. Leung JC, et al. *Kidney Int* 2001;59:277–85.
 37. Horie A, et al. *Am J Kidney Dis* 2003;42:486–96.
 38. Hiki Y. *Clin Exp Nephrol* 2009;13:415–23.
4. Mucosal immunity
1. Feehally J, et al. *Kidney Int* 1986;30:924–31.
 2. Hotta O, et al. *Am J Kidney Dis* 2001;38:736–43.
 3. Xie Y, et al. *Kidney Int* 2003;63:1861–7.
 4. Coppo R, et al. *J Nephrol* 2010;23:626–32.
 5. Boyd JK, et al. *Kidney Int* 2012;81:833–43.
 6. Leinikki PO, et al. *Clin Exp Immunol* 1987;68:33–8.
 7. van den Wall Bake AW, et al. *J Clin Invest* 1989;84:1070–5.
 8. Layward L, et al. *Clin Immunol Immunopathol* 1993;69:306–13.
 9. Barratt J, et al. *Am J Kidney Dis* 1999;33:1049–57.
 10. de Fijter JW, et al. *Kidney Int* 1996;50:952–61.
 11. Roodnat JJ, et al. *Nephrol Dial Transplant* 1999;14:353–9.
 12. van den Wall Bake AW, et al. *Clin Exp Immunol* 1988;72:321–5.
 13. van den Wall Bake AW, et al. *Kidney Int* 1989;35:1400–4.
 14. Harper SJ, et al. *J Clin Pathol* 1996;49:38–42.
 15. Westberg NG, et al. *Clin Immunol Immunopathol* 1983;26:442–5.
 16. Harper SJ, et al. *Kidney Int* 1994;45:836–44.
 17. Kunkel EJ, et al. *Nat Rev Immunol* 2003;3:822–9.
 18. Smith AC, et al. *J Am Soc Nephrol* 2006;17:3520–8.
 19. Barratt J, et al. *Nephrol Dial Transplant* 2009;24:3620–3.
 20. Batra A, et al. *Nephrol Dial Transplant* 2007;22:2540–8.
 21. Buren M, et al. *Contrib Nephrol* 2007;157:50–5.
 22. Gesualdo L, et al. *J Immunol* 1990;145:3684–91.
 23. Zadrazil J, et al. *J Nephrol* 2006;19:382–6.
 24. Chan SM, et al. *Br J Dermatol* 2007;156:143–7.
 25. Trimarchi HM, et al. *Am J Nephrol* 2001;21:400–5.
 26. Forshaw MJ, et al. *Int J Colorectal Dis* 2005;20:463–5.
 27. de Moura CG, et al. *J Clin Rheumatol* 2006;12:106–7.
 28. Wang J, et al. *J Clin Invest* 2004;113:826–35.
 29. Coppo R, et al. *Kidney Int* 2009;75:536–41.
 30. Coppo R, et al. *Clin Exp Immunol* 2010;159:73–81.
 31. Qin W, et al. *Nephrol Dial Transplant* 2008;23:1608–14.
 32. Suzuki H, et al. *J Am Soc Nephrol* 2008;19:2384–95.
 33. Sato D, et al. *Nephrol Dial Transplant* 2012;27:1090–7.
 34. Fujihashi K, et al. *J Exp Med* 1996;183:1929–35.
 35. Toyabe S, et al. *Clin Exp Immunol* 2001;124:110–7.
 36. Olive C, et al. *Kidney Int* 1997;52:1047–53.
 37. Wu H, et al. *Kidney Int* 1999;55:109–19.
 38. Buck KS, et al. *Clin Exp Immunol* 2002;127:527–32.
 39. Cox SN, et al. *Kidney Int* 2012;82:548–60.
 40. Goto T, et al. *Clin Immunol* 2008;126:260–9.
 41. McCarthy DD, et al. *J Clin Invest* 2011;121:3991–4002.
 42. Macpherson AJ, et al. *Trends Immunol* 2012;33:160–7.
 43. Jin J, et al. *Nat Immunol* 2012;13:1101–9.
 44. Marquina R, et al. *J Immunol* 2004;172:7177–85.
 45. Gonzalez J, et al. *J Immunol* 2007;178:2778–86.
 46. Murakata H, et al. *Acta Otolaryngol* 1999;119:384–91.
 47. Suzuki S, et al. *Lancet* 1994;343:12–6.
 48. Fujieda S, et al. *Clin Immunol* 2000;95:235–43.
 49. Nagy J, et al. *Scand J Immunol* 1988;27:393–9.
 50. Bene MC, et al. *Nephron* 1991;58:425–8.
 51. Egido J, et al. *Clin Exp Immunol* 1984;57:101–6.
 52. Inoue T, et al. *Clin Immunol* 2010;136:447–55.
 53. Horie A, et al. *Am J Kidney Dis* 2003;42:486–96.
 54. Xie Y, et al. *Kidney Int* 2004;65:1135–44.
 55. Baumgarth N. *Nat Rev Immunol* 2011;11:34–46.
 56. Kodama S, et al. *Clin Exp Immunol* 2001;123:301–8.
 57. Yuling H, et al. *J Am Soc Nephrol* 2008;19:2130–9.
 58. Nozawa H, et al. *Clin Exp Immunol* 2008;151:25–33.
 59. Johnson RJ, et al. *Am J Kidney Dis* 2003;42:575–81.
 60. Emancipator SN, et al. *J Exp Med* 1983;157:572–82.
 61. Ichinose H, et al. *Clin Exp Immunol* 1996;103:125–32.
 62. Ebihara I, et al. *Nephrol Dial Transplant* 2001;16:1783–9.
 63. Yano N, et al. *J Clin Immunol* 1997;17:396–403.
 64. Lim CS, et al. *Nephrol Dial Transplant* 2001;16:269–75.
 65. Suzuki H, et al. *Kidney Int* 2007;72:319–27.
 66. Suzuki Y, et al. *Contrib Nephrol* 2007;157:70–9.
 67. Mora JR, et al. *Mucosal Immunol* 2008;1:96–109.
 68. Yamada K, et al. *Nephrol Dial Transplant* 2010;25:3890–7.
 69. Coppo R, et al. *Clin Nephrol* 1990;33:72–86.
 70. Waldo FB, et al. *Lancet* 1989;1:129–31.
 71. Iwama H, et al. *Am J Kidney Dis* 1998;32:785–93.
 72. Koyama A, et al. *Kidney Int* 1995;47:207–16.
 73. Koyama A, et al. *Kidney Int* 2004;66:121–32.
 74. Schmitt R, et al. *Am J Pathol* 2010;176:608–18.
 75. Fornasieri A, et al. *Br Med J (Clin Res Ed)* 1987;295:78–80.
 76. Collin P, et al. *Am J Gastroenterol* 2002;97:2572–6.
 77. Pierucci A, et al. *Am J Kidney Dis* 2002;39:1176–82.
 78. Sategna-Guidetti C, et al. *Gut* 1992;33:476–8.
 79. Jackson S, et al. *Clin Exp Immunol* 1992;89:315–20.
 80. Russell MW, et al. *J Clin Immunol* 1986;6:74–86.
 81. Feehally J, et al. *Pediatr Nephrol* 1987;1:581–6.
 82. Sato M, et al. *Clin Exp Immunol* 1988;73:295–9.
 83. Smerud HK, et al. *Nephrol Dial Transplant* 2009;24:2476–81.
 84. Ferri C, et al. *Nephrol Dial Transplant* 1993;8:1193–8.
5. IgA1 glomerular deposition
1. Tomino Y, et al. *Am J Kidney Dis* 1982;1:276–80.
 2. Monteiro RC, et al. *Kidney Int* 1985;28:666–71.
 3. Conley ME, et al. *J Clin Invest* 1980;66:1432–6.
 4. van der Boog PJ, et al. *Kidney Int* 2005;67:813–21.
 5. Tomino Y, et al. *Clin Exp Immunol* 1982;49:419–25.
 6. Hiki Y, et al. *Kidney Int* 2001;59:1077–85.
 7. Allen AC, et al. *Kidney Int* 2001;60:969–73.
 8. Kokubo T, et al. *J Am Soc Nephrol* 1997;8:915–9.

9. Tomana M, et al. *Kidney Int* 1997;52:509–16.
 10. Tomana M, et al. *J Clin Invest* 1999;104:73–81.
 11. Suzuki H, et al. *J Clin Invest* 2009;119:1668–77.
 12. Berthoux F, et al. *J Am Soc Nephrol* 2012;23:1579–87.
 13. Novak J, et al. *Semin Nephrol* 2008;28:78–87.
 14. Suzuki H, et al. *J Am Soc Nephrol* 2011;22:1795–803.
 15. Levinsky RJ, et al. *Lancet* 1979;2:1100–3.
 16. Hall RP, et al. *Clin Exp Immunol* 1980;40:431–7.
 17. Hall RP, et al. *Clin Exp Immunol* 1981;45:234–9.
 18. Tissandie E, et al. *Kidney Int* 2011;80:1352–63.
 19. Novak J, et al. *Kidney Int* 2005;67:504–13.
 20. Glasscock RJ. *Curr Opin Nephrol Hypertens* 2011;20:153–60.
 21. Mauer SM, et al. *J Exp Med* 1973;137:553–70.
 22. Couser WG. *J Am Soc Nephrol* 2012;23:381–99.
 23. Lai KN. *Nat Rev Nephrol* 2012;8:275–83.
 24. Hiki Y. *Clin Exp Nephrol* 2009;13:415–23.
 25. Monteiro RC, et al. *Annu Rev Immunol* 2003;21:177–204.
 26. Moura IC, et al. *J Exp Med* 2001;194:417–25.
 27. Moura IC, et al. *J Am Soc Nephrol* 2004;15:622–34.
 28. McDonald KJ, et al. *Biochem Biophys Res Commun* 2002;290:438–42.
 29. Diven SC, et al. *Kidney Int* 1998;54:837–47.
 30. Leung JC, et al. *J Am Soc Nephrol* 2000;11:241–9.
 31. Novak J, et al. *Kidney Int* 2002;62:465–75.
 32. Westerhuis R, et al. *J Am Soc Nephrol* 1999;10:770–8.
 33. Barratt J, et al. *Kidney Int* 2000;57:1936–48.
 34. Kaneko Y, et al. *Int Immunol* 2012;24:219–32.
 35. Launay P, et al. *J Exp Med* 2000;191:1999–2009.
 36. Pleass RJ, et al. *J Biol Chem* 1999;274:23508–14.
 37. van der Boog PJ, et al. *Nephrol Dial Transplant* 2004;19:2729–36.
 38. van der Boog PJ, et al. *Kidney Int* 2003;63:514–21.
 39. Moura IC, et al. *J Am Soc Nephrol* 2005;16:2667–76.
 40. Haddad E, et al. *J Am Soc Nephrol* 2003;14:327–37.
 41. Berthelot L, et al. *J Exp Med* 2012;209:793–806.
 42. Kawabata H, et al. *J Biol Chem* 1999;274:20826–32.
 43. Itoh M, et al. *J Histochem Cytochem* 2011;59:180–7.
 44. Coppo R, et al. *Contrib Nephrol* 1993;104:162–71.
 45. Kokubo T, et al. *J Am Soc Nephrol* 1998;9:2048–54.
 46. Sano T, et al. *Nephrol Dial Transplant* 2002;17:50–6.
 47. Leung JC, et al. *Kidney Int* 2001;59:277–85.
 48. Leung JC, et al. *J Clin Lab Anal* 2002;16:11–9.
 49. Nishie T, et al. *Am J Pathol* 2007;170:447–56.
 50. Jennette JC, et al. *Am J Kidney Dis* 1991;18:466–71.
 51. Zheng F, et al. *Nat Med* 1999;5:1018–25.
 52. Narita I, et al. *Kidney Int* 2002;61:1853–8.
 53. Yong D, et al. *Am J Kidney Dis* 2006;48:1–7.
 54. Coppo R, et al. *Am J Kidney Dis* 2002;40:495–503.
 55. Hiki Y, et al. *J Am Soc Nephrol* 1996;7:955–60.
 56. Hiki Y, et al. *J Am Soc Nephrol* 1999;10:760–9.
 57. Iwase H, et al. *Biochem Biophys Res Commun* 1999;261:472–7.
 58. Mole CM, et al. *Nephron* 1995;71:75–8.
 59. Oortwijn BD, et al. *Kidney Int* 2006;69:1131–8.
 60. Zhang JJ, et al. *Nephrol Dial Transplant* 2008;23:207–12.
 61. Delacroix DL, et al. *J Clin Invest* 1983;71:358–67.
 62. van den Wall Bake AW, et al. *Am J Kidney Dis* 1988;12:410–4.
 63. Harper SJ, et al. *Am J Kidney Dis* 1994;24:888–92.
 64. van den Wall Bake AW, et al. *Clin Exp Immunol* 1988;72:321–5.
 65. van den Wall Bake AW, et al. *Kidney Int* 1989;35:1400–4.
 66. Pouria S, et al. *Semin Nephrol* 2008;28:27–37.
 67. Roccatello D, et al. *Am J Kidney Dis* 1989;14:354–60.
 68. Stockert RJ. *Physiol Rev* 1995;75:591–609.
 69. Leung JC, et al. *J Lab Clin Med* 1999;133:152–60.
 70. Grossetete B, et al. *Kidney Int* 1998;53:1321–35.
 71. van Zandbergen G, et al. *Nephrol Dial Transplant* 1998;13:3058–64.
 72. Montenegro V, et al. *J Rheumatol* 2000;27:411–7.
 73. Grossetete B, et al. *AIDS* 1995;9:229–34.
 74. Silvain C, et al. *J Immunol* 1995;155:1606–18.
 75. Hotta O, et al. *Am J Kidney Dis* 2002;39:493–502.
 76. Imasawa T, et al. *Kidney Int* 1999;56:1809–17.
 77. Gomez-Guerrero C, et al. *J Immunol* 1994;153:5247–55.
 78. Barratt J, et al. *J Am Soc Nephrol* 2005;16:2088–97.
 79. Lamm ME, et al. *Am J Pathol* 2008;172:31–6.
6. Glomerular damage
1. Barratt J, et al. *Semin Nephrol* 2011;31:349–60.
 2. Lai KN. *Nat Rev Nephrol* 2012;8:275–83.
 3. Novak J, et al. *Kidney Int* 2002;62:465–75.
 4. Lopez-Armada MJ, et al. *J Immunol* 1996;157:2136–42.
 5. Novak J, et al. *Kidney Int* 2005;67:504–13.
 6. van den Dobbelen ME, et al. *Kidney Int* 1994;46:512–9.
 7. Moura IC, et al. *J Am Soc Nephrol* 2005;16:2667–76.
 8. Oortwijn BD, et al. *J Am Soc Nephrol* 2006;17:3529–39.
 9. Lai KN, et al. *J Am Soc Nephrol* 2003;14:3127–37.
 10. Leung JC, et al. *Nephrol Dial Transplant* 2003;18:36–45.
 11. Coppo R, et al. *Kidney Int* 2010;77:417–27.
 12. Amore A, et al. *J Am Soc Nephrol* 2001;12:1862–71.
 13. Amore A, et al. *Am J Kidney Dis* 2000;36:1242–52.
 14. Lai KN, et al. *Kidney Int* 2004;66:1403–16.
 15. Miyake-Ogawa C, et al. *Am J Nephrol* 2005;25:1–12.
 16. Tamouza H, et al. *Kidney Int* 2012;82:1284–96.
 17. Kim MJ, et al. *J Immunol* 2012;189:3751–8.
 18. Rauterberg EW, et al. *Kidney Int* 1987;31:820–9.
 19. Stad RK, et al. *Clin Exp Immunol* 1993;92:514–21.
 20. Matsuda M, et al. *Nephron* 1998;80:408–13.
 21. Roos A, et al. *J Immunol* 2001;167:2861–8.
 22. Roos A, et al. *J Am Soc Nephrol* 2006;17:1724–34.
 23. Zwirner J, et al. *Kidney Int* 1997;51:1257–64.
 24. Kim SJ, et al. *PLoS One* 2012;7:e40495.
 25. Montinaro V, et al. *J Am Soc Nephrol* 1997;8:415–25.
 26. Abe K, et al. *Nephron* 2001;87:231–9.
 27. Abe K, et al. *Kidney Int* 1998;54:120–30.

28. Endo M, et al. *Nephrol Dial Transplant* 1998;13:1984–90.
 29. Lhotta K, et al. *Nephrol Dial Transplant* 1999;14:881–6.
 30. Floege J. *Nephron* 2002;91:582–7.
 31. Asao R, et al. *Clin J Am Soc Nephrol* 2012;
 32. Remuzzi G, et al. *N Engl J Med* 1998;339:1448–56.
 33. Lai KN, et al. *Nephrol Dial Transplant* 2009;24:62–72.
 34. El Karoui K, et al. *Kidney Int* 2011;79:643–54.
 35. Hill GS, et al. *Kidney Int* 2011;79:635–42.
 36. Cook HT. *Kidney Int* 2011;79:581–3.
 37. Tam KY, et al. *Am J Physiol Renal Physiol* 2010;299:F359–68.
 38. Chan LY, et al. *Kidney Int* 2005;67:602–12.
 39. Xiao J, et al. *Clin Immunol* 2009;132:266–76.
 40. Wang L, et al. *J Lab Clin Med* 2003;142:313–21.
 41. Chan LY, et al. *J Am Soc Nephrol* 2005;16:2306–17.
 22. Sinnassamy P, et al. *Am J Kidney Dis* 1985;5:267–9.
 24. Moriyama T, et al. *Int Urol Nephrol* 2012;44:1177–84.
 25. Kim SM, et al. *J Korean Med Sci* 2009;24 Suppl:S44–9.
 26. KDIGO clinical practice guideline for glomerulonephritis. Chapter 10:Immunoglobulin A nephropathy. *Kidney Int Suppl* 2012;2:209–17.
 27. Committee for Diagnostic Guidelines of Hematuria. *Nihon Jinzo Gakkai Shi*. 2006;48 Suppl:1-34
 28. Walshe JJ, et al. *Am J Med* 1984;77:765–7.
 29. MacDonald I, et al. *Clin Nephrol* 1975;3:129–33.
 30. Schena FP, et al. *Oxford Textbook of Clinical Nephrology*. 3rd ed. 2006;1:469–501.
 31. Gutiérrez E, et al. *Clin J Am Soc Nephrol* 2007;2:51–7.
 32. Yoshikawa N, et al. *Clin Nephrol* 1987;28:217–21.
 33. Bennett WM, et al. *Kidney Int* 1983;23:393–400.
 34. Praga M, et al. *Kidney Int* 1985;28:69–74.
 35. Delclaux C, et al. *Nephrol Dial Transplant* 1993;8:195–9.
 36. Matousov K, et al. *Nephrol Dial Transplant* 2006;21:2478–84.
 37. Obara T, et al. *Clin Exp Nephrol* 2012;16:713–21.
 38. Nakamura T, et al. *Am J Nephrol* 2005;25:447–50.
 39. Moon PG, et al. *Proteomics* 2011;11:2459–75.
 40. Tomino Y, et al. *J Clin Lab Anal* 2000;14:220–3.
 41. Miyazaki R, et al. *Clin Nephrol* 1984;21:335–40.
 42. Wyatt RJ, et al. *Kidney Int* 1987;31:1019–23.
 43. Maeda A, et al. *J Clin Lab Anal* 2003;17:73–6.
 44. Nakayama K, et al. *J Clin Lab Anal* 2008;22:114–8.
 45. Jones CL, et al. *Kidney Int* 1990;38:323–31.
 46. Allen AC, et al. *Clin Exp Immunol* 1995;100:470–4.
 47. Tomana M, et al. 1997;52:509–16.
 48. Hiki Y, et al. *Kidney Int* 2001;59:1077–85.
 49. Moldoveanu Z, et al. *Kidney Int* 2007;71:1148–54.
 50. Gharavi AG, et al. *J Am Soc Nephrol* 2008;19:1008–14.
 51. Czerkinsky C, et al. *J Clin Invest* 1986;77:1931–8.
 52. Coppo R, et al. *Clin Nephrol* 1995;43:1–13.
 53. Schena FP, et al. *Clin Exp Immunol* 1989;77:15–20.
 54. Allen AC, et al. *Kidney Int* 2001;60:969–73.
 55. Suzuki H, et al. *J Clin Invest* 2009;119:1668–77.
 56. Hastings MC, et al. *Clin J Am Soc Nephrol* 2010;5:2069–74.
 57. Donadio JV, et al. *Nephrol Dial Transplant* 2002;17:1197–203.
 58. D'Amico G, et al. *Q J Med* 1986;59:363–78.
 59. Reich HN, et al. *J Am Soc Nephrol* 2007;18:3177–83.
 60. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. *Kidney Int* 2009;76:534–45.
 61. Herzenberg AM, et al. *Kidney Int* 2011;80:310–7.
 62. Hsu SI, et al. *Kidney Int* 2000;57:1818–35.
 63. Karnib HH, et al. *Nephrol Dial Transplant* 2007;22:772–7.
 64. Schena FP, et al. *J Am Soc Nephrol* 2002;13:453–60.
 65. Gharavi AG, et al. *Nat Genet* 2000;26:354–7.
- ## II. Diagnosis
- ### 1. Diagnosis
1. Nakayama K, et al. *J Clin Lab Anal* 2008;22:114–8.
 2. Dische FE, et al. *Am J Nephrol* 1985;5:103–9.
 3. Aarons I, et al. *Clin Nephrol* 1989;32:151–8.
 4. Packham DK. *Nephrology(Carlton)*2007;12:481–6.
 5. Donadio JV, et al. *N Engl J Med* 2002;347:738–48.
 6. Saulsbury FT. *Medicine(Baltimore)*1999;78:395–409.
- ### 2. Clinical manifestations and laboratory findings
1. Ponticelli C, et al. *Kidney Int* 2001;60:1948–54.
 2. Sakai H, et al. *The Achievements of Progressive Renal Diseases Research, Research on intractable disease, the Ministry of Health, Labour and Welfare of Japan* 1995. 1996;1–5 (Japanese).
 3. Floege J, et al. *J Am Soc Nephrol* 2000;11:2395–403.
 4. Donadio JV, et al. *N Engl J Med* 2002;347:738–48.
 5. Coppo R, et al. *J Nephrol* 2005;18:503–12.
 6. D'Amico G. *Am J Kidney Dis* 1988;12:353–7.
 7. D'Amico G. *Nephron* 1985;41:1–13.
 8. D'Amico G, et al. *Medicine (Baltimore)*1985;64:49–60.
 9. D'Amico G. *Q J Med* 1987;6:709–27.
 10. Neelakantappa K, et al. *Kidney Int* 1988;33:716–21.
 11. Perez-Fontan M, et al. *Am J Nephrol* 1986;6:482–6.
 12. Research Group on Progressive Chronic Renal Disease. *Nephron* 1999;82:205–13.
 13. Sugiyama H, et al. *Clin Exp Nephrol* 2011;15:493–503.
 14. Matutani S, et al. *Acta Otolaryngol Suppl* 2004;555:58–61.
 15. Yamabe H, et al. *Acta Otolaryngol Suppl* 1996;523:169–71.
 16. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. *Nihon Jinzo Gakkai Shi*. 2011; 53(2):123–35.
 17. Cohen RA, et al. *N Engl J Med* 2003;348:2330–8.
 18. Birch DF, et al. *Clin Nephrol* 1983;20:78–84.
 19. Murakami S, et al. *J Urol* 1990;144:99–101.
 20. Grossfeld GD, et al. *Am Fam Physician* 2001;63:1145–54.
 21. Philibert D, et al. *Semin Nephrol* 2008;28:10–7.
 22. Lai KN, et al. *Am J Clin Pathol* 1986;86:716–23.
- ### 3. Pathological findings
1. Sugiyama H, et al. *Clin Exp Nephrol* 2013;17:155–73.
 2. Hennigar RA, et al. *Silva's Diagnostic Renal Pathology*. Cambridge 2009;pp127–77.

3. Zidar N, et al. *Kidney Int* 1992;42:1444–9.
 4. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int* 2009;76:534–45.
 5. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. *Kidney Int* 2009;76:546–56.
 6. Clinical guides for immunoglobulin A (IgA) nephropathy in Japan, third version. *Nihon Jinzo Gakkai Shi*. 2011; 53(2):123–35.
 7. Histological atlas of immunoglobulin (IgA) nephropathy. *Nihon Jinzo Gakkai Shi*. 2011; 53(5): 655–66. (Japanese)
 8. Hass M. *Heptinstall's Pathology of the Kidney*, 6th ed., vol. 1 (Lippincott Williams & Wilkins) 2007;423–86.
 9. Suzuki K, et al. *Kidney Int* 2003;63:2286–94.
 10. D'Amico G. *Semin Nephrol* 2004;24:179–96.
 11. Herzenberg AM, et al. *Kidney Int* 2011;80:310–7.
 12. Shi SF, et al. *Clin J Am Soc Nephrol* 2011;6:2175–84.
 13. Yau T, et al. *Am J Nephrol* 2011;34:435–44.
 14. Kang S, et al. *Nephrol Dial Transplant* 2012;27:252–8.
 15. Alamartine E, et al. *Clin J Am Soc Nephrol* 2011;6:2384–88.
 16. Tsuboi N, et al. *Clin J Am Soc Nephrol* 2010;5:39–44.
 17. Haas M. *Am J Kidney Dis* 1997;29:829–42.
 18. Katafuchi R, et al. *Clin J Am Soc Nephrol* 2011;6:2806–13.
 19. Walsh M, et al. *Clin J Am Soc Nephrol* 2010;5:423–30.
 20. Bellur SS, et al. *Nephrol Dial Transplant* 2011;26:2533–8.
 21. Working group of the international IgA nephropathy network and the Renal Pathology Society, The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. *Kidney Int* 2010;77:921–7.
 22. Ikezumi Y, et al. *Nephrol Dial Transplant* 2006;21:3466–74.
 23. Shima Y, et al. *Pediatr Nephrol* 2012;27:783–92.
 24. Halling SE, et al. *Nephrol Dial Transplant* 2012;27:715–22
4. Classification
1. Lee SM, et al. *Hum Pathol* 1982;13:314–22.
 2. Meadow SR, et al. *Q J Med* 1972;41:241–58.
 3. Lee HS, et al. *Clin Nephrol* 1987;27:131–40.
 4. Lee HS, et al. *Nephrol Dial Transplant* 2005;20:342–8.
 5. Haas M. *Am J Kidney Dis* 1997;29:829–42.
 6. Manno C, et al. *Am J Kidney Dis* 2007;49:763–75.
 7. Alamartine E, et al. *Clin Nephrol* 1990;34:45–51.
 8. Radford MG Jr, et al. *J Am Soc Nephrol* 1997;8:199–207.
 9. Shigematsu H. *Pathol Int* 1997;47:194–202.
 10. Katafuchi R, et al. *Clin Nephrol* 1998;49:1–8.
 11. Magistroni R, et al. *J Nephrol* 2006;19:32–40.
 12. Okonogi H, et al. *Nephron Clin Pract* 2011;118:c292–300.
 13. Wakai K, et al. *Nephrol Dial Transplant* 2006;21:2800–8.
 14. Goto M, et al. *Nephrol Dial Transplant* 2009;24:3068–74.
 15. Goto M, et al. *Nephrol Dial Transplant* 2009;24:1242–7.
 16. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. *Kidney Int* 2009;76:546–56.
 17. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. *Kidney Int* 2009;76:534–45.
 18. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. *Kidney Int* 2010;77:921–7.
 19. Herzenberg AM, et al. *Kidney Int* 2011;80:310–7.
 20. Yau T, et al. *Am J Nephrol* 2011;34:435–44.
 21. Shi SF, et al. *Clin J Am Soc Nephrol* 2011;6:2175–84.
 22. Alamartine E, et al. *Clin J Am Soc Nephrol* 2011;6:2384–8.
 23. Katafuchi R, et al. *Clin J Am Soc Nephrol* 2011;6:2806–13.
 24. Kang SH, et al. *Nephrol Dial Transplant* 2012;27:252–8.
 25. Edström Halling S, et al. *Nephrol Dial Transplant* 2012;27:715–22.
 26. Shima Y, et al. *Pediatr Nephrol* 2012;27:783–92.
 27. Kawamura T, et al. *J Nephrol* 2013;26:350–7.
5. Atypical forms of IgA nephropathy
1. Minimal change nephrotic disease (MCD) with mesangial IgA deposits
 1. Mustonen J, et al. *Clin Nephrol* 1983;20:172.6.
 2. Lai KN, et al. *Am J Clin Pathol* 1986;86:716.23.
 3. Lai KN, et al. *Clin Nephrol* 1986;26:174.80.
 4. Fukushi K, et al. *Jpn J Nephrol* 1988;30:253.8.
 5. Kim SM, et al. *J Korean Med Sci* 2009;24 Suppl:S44.9.
 2. Acute kidney injury (AKI) associated with macroscopic hematuria
 1. Bennett WM, et al. *Kidney Int* 1983;23:393–400.
 2. Praga M, et al. *Kidney Int* 1985;28:69–74.
 3. Delclaux C, et al. 1993;8:195–9.
 4. Kveder R, et al. *Ther Apher Dial* 2009;13:273–7.
 5. Gutiérrez E, et al. *Clin J Am Soc Nephrol* 2007;2:51–7.
 3. Crescentic IgA nephropathy
 1. Abuelo JG, et al. *Medicine(Baltimore)*1984;63:396–406.
 2. Roccatello D, et al. *Nephrol Dial Transplant* 1995;10:2054–9.
 3. Chambers ME, et al. *J Clin Apher* 1999;14:185–7.
 4. Tumlin JA, et al. *Nephrol Dial Transplant* 2003;18:1321–9.
 5. Bazzi C, et al. *Clin J Am Soc Nephrol* 2009;4:929–35.
 6. Lai KN, et al. *Am J Kidney Dis* 1987;10:66–70.
 7. Welch TR, et al. *Am J Dis Child* 1988;142:789–93.
 8. Harper L, et al. *J Nephrol* 2000;13:360–6.
 9. Nicholls K, et al. *Am J Kidney Dis* 1985;5:42–6.
 10. Coppo R, et al. *Int J Artif Organs* 1985;Suppl 2:55–8.
 11. McIntyre CW, et al. *Clin Nephrol* 2001;56:193–8.
 12. Tang Z, et al. *Am J Nephrol* 2002;22:480–6.
- III. Epidemiology, prognosis, and follow-up
1. Incidence and prevalence
 1. Donadio JV, et al. *N Engl J Med* 2002;347:738–48.
 2. Utsunomiya Y, et al. *Pediatr Nephrol* 2003;18:511–5.
 3. McGrogan A, et al. *Nephrol Dial Transplant* 2011;26:414–30.
 2. Natural course
 1. Shen P, et al. *Nephron Clin Pract* 2007;106:c157–61.
 2. Chauveau D, et al. *Contrib Nephrol* 1993;104:1–5.
 3. Koyama A, et al. *Am J Kidney Dis* 1997;29:526–32.

4. D'Amico G. *Semin Nephrol* 2004;24:179–96.
 5. Kusumoto Y, et al. *Clin Nephrol* 1987;28:118–24.
3. Changes in prognosis with changes in treatment guidelines
1. Komatsu H, et al. *Am J Nephrol* 2009;30:19–25.
 2. Yata N, et al. *Pediatr Nephrol* 2008;23:905–12.
 3. Asaba K, et al. *Intern Med* 2009;48:883–90.
4. Clinical predictors of progression at the time of initial examination or renal biopsy
1. Wakai K, et al. *Nephrol Dial Transplant* 2006;21:2800–8.
 2. Manno C, et al. *Am J Kidney Dis* 2007;49:763–75.
 3. Goto M, et al. *Nephrol Dial Transplant* 2009;24:3068–74.
 4. Berthoux F, et al. *J Am Soc Nephrol* 2011;22:752–61.
 5. D'Amico G. *Semin Nephrol* 2004;24:179–96.
 6. Eiro M, et al. *Nephron* 2002;90:432–41.
 7. Ieiri N, et al. *Clin Exp Nephrol* 2012;16:122–9.
5. Clinical predictors of progression during follow-up
1. Kobayashi Y, et al. *Nephrology* 1997;3:35–40.
 2. Bartosik LP, et al. *Am J Kidney Dis* 2001;38:728–35.
 3. Donadio JV, et al. *Nephrol Dial Transplant* 2002;17:1197–203.
 4. Reich HN, et al. *J Am Soc Nephrol* 2007;18:3177–83.
 5. Berthoux F, et al. *J Am Soc Nephrol* 2011;22:752–61.
 6. Le WB, et al. *Nephrol Dial Transplant* 2012;27:1479–85.
 7. Pozzi C, et al. *J Am Soc Nephrol* 2004;15:157–63.
 8. Cheng J, et al. *Int J Clin Pract* 2009;63:880–8.
 9. Lv J, et al. *Am J Kidney Dis* 2009;53:26–32.
 10. Manno C, et al. *Nephrol Dial Transplant* 2009;24:3694–701.
 11. Hwang HS, et al. *Nephrology* 2010;15:236–41.
 12. Payton CD, et al. *Nephrol Dial Transplant* 1988;3:138–42.
6. Remission of urinary findings and its significance
1. Hotta O, et al. *Am J Kidney Dis* 2001;38:736–43.
 2. Komatsu H, et al. *Clin J Am Soc Nephrol* 2008;3:1301–7.
 3. Miura N, et al. *Clin Exp Nephrol* 2009;13:460–6.
 4. Kawaguchi T, et al. *Nephrology* 2010;15:116–23.
 5. Tatematsu M, et al. *Clin Exp Nephrol* 2012:1–9.
 6. Hwang HS, et al. *Nephrology* 2010;15:236–41.
 7. Pozzi C, et al. *Lancet* 1999;353:883–7.
 8. Hotta O, et al. *Am J Kidney Dis* 2002;39:493–502.
 9. Matsuzaki K, et al. *Clin Exp Nephrol* 2013;17:827–33.
7. Follow-up
1. Hotta O, et al. *Am J Kidney Dis* 2001;38:736–43.
 2. Szeto C, et al. *Am J Med* 2001;110:434–37.
 3. Shen P, et al. *Nephron Clin Pract* 2007;106:c157–61.
 4. Goto M, et al. *Nephrol Dial Transplant* 2009;24:3068–74.
 5. Goto M, et al. *Nephrol Dial Transplant* 2009;24:1242–7.
 6. Shen P, et al. *Neth J Med* 2008;66:242–7.

IV. Treatment

1. A summary of management of IgAN in adults, with a focus on prevention of renal dysfunction
2. Clinical questions (CQs) about immunosuppressive therapy (adults)
 - CQ 1. Are corticosteroids recommended in IgA nephropathy?
 1. Lv J, et al. *J Am Soc Nephrol* 2012;23:1108–16 (Level 1)
 2. Zhou YH, et al. *PLoS One* 2011;6:e18788 (Level 4)
 3. Cheng J. *Am J Nephrol* 2009;30:315–22 (Level 1)
 4. Samuels JA, et al. *Cochrane Database Syst Rev* 2003;4:CD003965 (Level 3)
 5. Lv J, et al. *Am J Kidney Dis* 2009;53:26–32 (Level 2)
 6. Manno C, et al. *Nephrol Dial Transplant* 2009;24:3694–701 (Level 2)
 7. Pozzi C, et al. *Lancet* 1999;353:883–7 (Level 2)
 8. Pozzi C, et al. *J Am Soc Nephrol* 2004;15:157–63 (Level 2)
 9. Lai KN, et al. *Clin Nephrol* 1986;26:174–80 (Level 2)
 10. Julian BA, et al. *Contrib Nephrol* 1993;104:198–206 (Level 2)
 11. Katafuchi R, et al. *Am J Kidney Dis* 2003;41:972–83 (Level 2)
 12. Hogg RJ. *Clin J Am Soc Nephrol* 2006;1:467–74 (Level 2)
 13. Koike M, et al. *Clin Exp Nephrol* 2008;12:250–5 (Level 2)
 14. Shoji T, et al. *Am J Kidney Dis* 2000;35:194–201 (Level 2)
 - CQ 2. Is tonsillectomy combined with steroid pulse therapy recommended?
 1. Hotta O, et al. *Am J Kidney Dis* 2001;38:736–43 (Level 4)
 2. Kawaguchi T, et al. *Nephrology(Carlton)*2010;15:116–23 (Level 4)
 3. Sato M, et al. *Nephron Clin Pract* 2003;93:c137–45 (Level 4)
 4. Komatsu H, et al. *Clin J Am Soc Nephrol* 2008;3:1301–7 (Level 3)
 5. Miura N, et al. *Clin Exp Nephrol* 2009;13:460–6 (Level 4)
 6. Hotta O, et al. *Jpn J Nephrol* 1993;35:967–73 (Level 4)
 7. Hotta O, et al. *Acta Otolaryngol Suppl* 1996;523:165–8 (Level 4)
 8. Kawamura T, et al. *Nephrol Dial Transplant* 2014;29:1546–53
 - CQ 3. Is tonsillectomy (alone) recommended?
 1. Iino Y, et al. *Acta Otolaryngol Suppl* 1993;508:29–35 (Level 4)
 2. Kosaka M. *Nihon Jibiinkoka Gakkai Kaiho* 1998;101:916–23 (Level 4)
 3. Rasche FM, et al. *Clin Nephrol* 1999;51:147–52 (Level 4)
 4. Chen, Y, et al. *Am J Nephrol* 2007;27:170–5 (Level 4)
 5. Xie, Y, et al. *Kidney Int* 2003;63:1861–7 (Level 4)
 6. Akagi H, et al. *Acta Otolaryngol Suppl* 2004;555:38–42 (Level 4)
 7. Wang, Y, et al. *Nephrol Dial Transplant* 2011;26:1923–31 (Level 4)
 8. Komatsu H, et al. *Ren Fail* 2012;34:448–53 (Level 4)
 9. Maeda I, et al. *Nephrol Dial Transplant* 2012;27:2806–13 (Level 4)

CQ 4. Are non-steroidal immunosuppressive agents recommended?

1. Walker RG, et al. *Clin Nephrol* 1990;34:103–7 (Level 2)
2. Ballardie FW, et al. *J Am Soc Nephrol* 2002;13:142–8 (Level 2)
3. Pozzi C, et al. *J Am Soc Nephrol* 2010;21:1783–90 (Level 2)
4. Harmankaya O, et al. *Int Urol Nephrol* 2002;33:167–71 (Level 2)
5. Lai KN, et al. *BMJ* 1987;295:1165–8 (Level 2)
6. Frisch G, et al. *Nephrol Dial Transplant* 2005;20:2139–45 (Level 2)
7. Tang S, et al. *Kidney Int* 2005;68:802–12 (Level 2)
8. Maes BD, et al. *Kidney Int* 2004;65:1842–9 (Level 2)
9. Xu G, et al. *Am J Nephrol* 2009;29:362–7 (Level 1)
10. Xie Y, et al. *Am J Med Sci* 2011;341:367–72 (Level 2)

3. CQs about immunosuppressive therapy (children)

CQ 5. Is immunosuppressive therapy recommended in childhood IgA nephropathy?

1. Yoshikawa N, et al. *Pediatr Nephrol* 2001;16:446–57.
2. Yoshikawa N, et al. *Nihon Jinzo Gakkai Shi.* 1997 Jul;39(5):503–6.
3. Yoshikawa N, et al. *J Am Soc Nephrol* 1999;10:101–9 (Level 2)
4. Yata N, et al. *Pediatr Nephrol* 2008;23:905–12 (Level 4)
5. Kamei K, et al. *Clin J Am Soc Nephrol* 2011;6:1301–7 (Level 2)

CQ 6. Is combination “cocktail” therapy recommended in childhood IgA nephropathy?

1. Yoshikawa N, et al. *J Am Soc Nephrol* 1999;10:101–9 (Level 2)
2. Yoshikawa N, et al. *Clin J Am Soc Nephrol* 2006;1:511–7 (Level 2)
3. Kamei K, et al. *Clin J Am Soc Nephrol* 2011;6:1301–7 (Level 2)
4. Yoshikawa N, et al. *Pediatr Nephrol* 2008;23:757–63 (Level 4)
5. Pozzi C, et al. *J Am Soc Nephrol* 2010;21:1783–90.

4. CQs about supportive therapy (adults)

CQ 7. Are RAS blockers recommended in IgA nephropathy?

1. Cheng J, et al. *Int J Clin Pract* 2009;63:880–8 (Level 1)
2. Reid S, et al. *Cochrane Database Syst Rev* 2011;3:CD003962 (Level 1)
3. Praga M, et al. *J Am Soc Nephrol* 2003;14:1578–83 (Level 2)
4. Woo KT, et al. *Cell Mol Immunol* 2007;4:227–32 (Level 2)
5. Ruggenenti P, et al. *Am J Kidney Dis* 2000;35:1155–65 (Level 2)
6. Woo KT, et al. *Kidney Int* 2000;58:2485–91 (Level 2)
7. Park HC, et al. *Nephrol Dial Transplant* 2003;18:1115–21 (Level 2)
8. Li PK, et al. *Am J Kidney Dis* 2006;47:751–60 (Level 2)
9. Nakamura T, et al. *Am J Nephrol* 2000;20:373–9 (Level 2)
10. Coppo R, et al. *J Am Soc Nephrol* 2007;18:1880–8 (Level 2)
11. Horita Y, et al. *Hypertens Res* 2004;27:963–70 (Level 2)

12. Nakamura T, et al. *Am J Hypertens* 2007;20:1195–201 (Level 2)

CQ 8. Are antiplatelet agents recommended in IgA nephropathy?

1. Taji Y, et al. *Clin Exp Nephrol* 2006;10:268–73 (Level 4)
2. Liu XJ, et al. *Intern Med* 2011;50:2503–10 (Level 1)
3. Chan MK, et al. *Am J Kidney Dis* 1987;9:417–21 (Level 2)
4. Lee GSL, et al. *Nephrology* 1997;3:117–21 (Level 2)
5. Camara S, et al. *Nephron* 1991;58:13–6 (Level 2)
6. Cheng I, et al. *Nephrology* 1998;4:19–26 (Level 2)

CQ 9. Are n-3 fatty acids (fish oil) recommended in IgA nephropathy?

1. Miller ER, et al. *Am J Clin Nutr* 2009;89:1937–45 (Level 4)
2. Bennett WM, et al. *Clin Nephrol* 1989;31:128–31 (Level 2)
3. Pettersson EE, et al. *Clin Nephrol* 1994;41:183–90 (Level 2)
4. Donadio JV, Jr., et al. *J Am Soc Nephrol* 1999;10:1772–7 (Level 2)
5. Alexopoulos E, et al. *Ren Fail* 2004;26:453–9 (Level 2)
6. Ferraro PM, et al. *Nephrol Dial Transplant* 2009;24:156–60 (Level 2)
7. Liu LL, et al. *Clin Nephrol* 2012;77:119–25 (Level 1)
8. Hogg RJ, et al. *Clin J Am Soc Nephrol* 2006;1:467–74 (Level 2)
9. Reid S, et al. *Cochrane Database Syst Rev* 2011;3:CD003962 (Level 1)
10. Donadio JV, Jr., et al. *N Engl J Med* 1994;331:1194–9 (Level 2)
11. Donadio JV Jr., et al. *J Am Soc Nephrol* 2001;12:791–9 (Level 2)

5. CQs about lifestyle and dietary guidance in IgA nephropathy

CQ 10. Should limitation of salt intake be recommended?

1. Vogt L, et al. *J Am Soc Nephrol* 2008;19:999–1007 (Level 2)
2. Slagman MC, et al. *BMJ* 2011;343:d4366 (Level 2)
3. Lin J, et al. *Clin J Am Soc Nephrol* 2010;5:836–43 (Level 4)
4. Vegter S, et al. *J Am Soc Nephrol* 2012;23:165–73 (Level 4)
5. Stolarz-Skrzypek K, et al. *JAMA* 2011;305:1777–85 (Level 4)
6. O'Donnell MJ, et al. *JAMA* 2011;306:2229–38 (Level 4)
7. Cook NR, et al. *BMJ* 2007;334:885–8 (Level 4)

CQ 11. Should restricted protein intake be recommended?

1. Pedrini MT, et al. *Ann Intern Med* 1996;124:627–32 (Level 3)
2. Fouque D, et al. *Cochrane Database Syst Rev* 2009;3:CD001892 (Level 1)
3. Kasiske BL, et al. *Am J Kidney Dis* 1998;31:954–61 (Level 1)
4. Koya D, et al. *Diabetologia* 2009;52:2037–45 (Level 2)
5. Cianciaruso B, et al. *Am J Kidney Dis* 2009;54:1052–61 (Level 2)
6. Menon V, et al. *Am J Kidney Dis* 2009;53:208–17 (Level 2)

CQ 12. Should weight loss be recommended?

1. Tanaka M, et al. *Nephron Clin Pract* 2009;112:c71–8 (Level 4)
2. Bonnet F, et al. *Am J Kidney Dis* 2001;37:720–7 (Level 4)

CQ 13. Should exercise restriction be recommended?

1. Fuiano G, et al. *Am J Kidney Dis* 2004;44:257–63 (Level 4)

2. Eidemak I, et al. *Nephron* 1997;75:36–40 (Level 4)
 3. Boyce ML, et al. *Am J Kidney Dis* 1997;30:180–92 (Level 4)
 4. Painter PL, et al. *Transplantation* 2002;74:42–8 (Level 4)
 5. Toyama K, et al. *J Cardiol* 2010;56:142–6 (Level 4)
 6. Pechter U, et al. *Int J Rehabil Res* 2003;26:153–6 (Level 4)
- CQ 14. Should smoking cessation be recommended?
1. Yamamoto R, et al. *Am J Kidney Dis* 2010;56:313–24 (Level 4)
 2. Orth SR, et al. *Kidney Int* 1998;54:926–31 (Level 4)
 3. Hallan SI, et al. *Kidney Int* 2011;80:516–23 (Level 4)
 4. Yamagata K, et al. *Kidney Int* 2007;71:159–66 (Level 4)
 5. Ishizaka N, et al. *Hypertens Res* 2008;31:485–92 (Level 4)
6. Adverse events associated with steroid therapy and immunosuppressive agents
1. Cheng J, et al. *Am J Nephrol* 2009;30:315–22 (Level 1)
 2. Lv J, et al. *J Am Soc Nephrol* 2012;23:1108–16. (Level 1)
 3. Zhou YH, et al. *PLoS One* 2011;6:e18788.(Level 1)
 4. Weinstein RS. *Endocrine* 2012;41:183–90.
 5. Drescher W, et al. *Nephrol Dial Transplant* 2011;26:2728–31.
 6. Fujimoto S, et al. *Am J Nephrol* 1990;10:231–6. (Level 4)
 7. Ballardie FW, et al. *J Am Soc Nephrol* 2002;13:142–8.(Level 2)
 8. Pozzi C, et al. *J Am Soc Nephrol* 2010;21:1783–90. (Level 2)
 9. Stangou M, et al. *Clin Exp Nephrol* 2011;15:373–80. (Level 2)
 10. Maes BD, et al. *Kidney Int* 2004;65:1842–9. (Level 2)
 11. Tang S, et al. *Kidney Int* 2005;68:802–12. (Level 2)
 12. Frisch G, et al. *Nephrol Dial Transplant* 2005;20:2139–45.(Level 2)
 13. Yoshikawa N, et al. *Clin J Am Soc Nephrol* 2006;1:511–7.(Level 2)
 14. Yoshikawa N, et al. *J Am Soc Nephrol* 1999;10:101–9.(Level 2)
 15. Yoshikawa N, et al. *Pediatr Nephrol* 2008;23:757–63.(Level 4)
 16. Salonen A, et al. *Laryngoscope* 2002;112:94–8.
 17. Heiser C, et al. *Laryngoscope* 2010;120:2119–24.
 18. Heiser C, et al. *Laryngoscope* 2012;122:1265–6.
 19. Windfuhr JP, et al. *Eur Arch Otorhinolaryngol* 2010;267:289–93.
 20. Windfuhr JP, et al. *Ann Otol Rhinol Laryngol* 2003;112:63–70.
 21. Lowe D, et al. *Lancet* 2004;364:697–702.
 22. Walker P, et al. *Otolaryngol Head Neck Surg* 2007;136(4 Suppl):S27–31.
 23. Arnoldner C, et al. *Wien Klin Wochenschr* 2008;120:336–42.
 24. Hessén Söderman AC, et al. *Laryngoscope* 2011;121:2322–6.
 25. Tomkinson A, et al. *Laryngoscope* 2011;121:279–88.
 26. Kennoki T, et al. *Transplantation* 2009;88:935–41.
 27. Kurata N, et al. *Nihon Jibiinkoka Gakkai Kaiho*.2012 Jan;115(1):29–36.
 30. Pratt LW. *Trans Am Acad Ophthalmol Otolaryngol* 1970;74:1146–54.